Archive for the ‘Life Extension’ Category

The RNLI has today Tuesday 10 March 2020 announced that it will extend the life of its Severn class lifeboats so they can continue saving lives at sea for another 25 years.

The largest and most powerful class of lifeboat, the Severn entered service back in 1996 and there are currently 44 of these 42 tonne lifesaving vessels in the charitys fleet. With an operational lifespan of 25 years, these amazing lifeboats are now approaching retirement age and are due to come off service soon.

However, the charitys expert in-house engineering team has worked in partnership with academic and industry experts, establishing that the lifeboats hulls can continue operational service for another 25 years. Through a life extension upgrade, the Severns wheelhouse will be completely redesigned and a wide range of upgrades will be made, ensuring the vessels can operate safely and effectively for another 25 years.

As well as fitting the lifeboats out with more modern and sophisticated technology and systems, the upgraded Severns will have significant safety enhancements to ensure the RNLIs volunteer crews are as safe as possible while out saving lives at sea in all weathers.

Nick Fenwick is Project Manager for the RNLIs Severn life extension programme. He said: From shock-mitigating seats for the crew, to new survivor space seating for casualties and a new daughter craft that can be launched quickly for rescuing casualties in shallow waters or close to rocks, the life extension upgrades will ensure our Severn class lifeboats are ready to save lives at sea for another 25 years.

The upgrades will bring the technology and systems onboard the Severn class lifeboats right up to date. A key upgrade will be the installation of the Systems and Information Management System, also known as SIMS.

Similar to the SIMS systems in our Tamar and Shannon class lifeboats, it is an electronic integrated bridge system that allows the crew to monitor, operate and control many of the lifeboats functions directly from their seats. These functions include the navigation and the mechanics of the lifeboat, such as the engines, bilge and electrics. This greatly increases our crews safety, reducing the need for them to walk around the lifeboat in the rough and challenging sea conditions they so often face.

An allocation of six Severn class lifeboats will be upgraded initially, with the upgrades taking place at the RNLIs All-weather Lifeboat Centre in Poole, Dorset. Work is already underway on the first vessel to receive its life extension upgrade, with a relief fleet Severn being worked on now with the aim of undertaking sea trials at the end of the year.

The first five lifeboat stations due to receive a life extended Severn are Aberdeen, Kirkwall and Lerwick in Scotland, Tynemouth in the north east of England and Ballyglass in the Republic of Ireland. Aberdeen Lifeboat Station are due to receive the first upgraded Severn at the end of 2021.

The average anticipated cost of each life extension upgrade is 1.25M. This is significantly less than the cost of designing and building a brand-new class of lifeboat to replace the Severn. For context, a Shannon, which is significantly smaller and not as powerful as the Severn, costs 2.2M to build.

Since entering service back in 1996, Severn class lifeboats have launched over 16,500 times, going to the aid of over 22,500 people and saving over 900 lives.

Angus Watson, Engineering and Supply Director, said: I am so excited to announce our plans to extend the operational life of our Severn class lifeboats.

Our Severns are often located in the more remote locations across the UK and Ireland, where the crews are often required to sail out longer distances in the most challenging sea conditions. Being the largest class of lifeboat, it is well-suited for locations where mass casualty rescues are more likely, and its highly elevated upper steering position and greater length are ideal when negotiating large waves in the roughest seas.

While the systems and technology on board the Severn class need upgrading, the lifeboats hull and structure is still ideally suited to the challenging conditions these lifeboats face today. So rather than spending significantly more money to roll out a brand new class of all-weather lifeboat, supplying stations with upgraded Severn class lifeboats that we know can meet the demands of these challenging stretches of coastline is a much more efficient use of charitable funds, while still ensuring that our volunteer crews have lifeboats absolutely fit for purpose for the next 25 years.

The RNLI has launched its Save our Severns appeal, with the aim of raising 700,000 to help fund life extension upgrades to these incredible vessels. To donate, visit:RNLI.org/Severn25

The RNLI charity saves lives at sea. Its volunteers provide a 24-hour search and rescue service around the United Kingdom and Republic of Ireland coasts. The RNLI operates over 238 lifeboat stations in the UK and Ireland and more than 240 lifeguard units on beaches around the UK and Channel Islands. The RNLI is independent of Coastguard and government and depends on voluntary donations and legacies to maintain its rescue service. Since the RNLI was founded in 1824, its lifeboat crews and lifeguards have saved over 142,700 lives.

For more information please visit the RNLI website or Facebook, Twitter and YouTube. News releases, videos and photos are available on the News Centre.

Members of the public may contact the RNLI on 0300 300 9990 (UK) or 1800 991802(Ireland) oror by email.

Originally posted here:
The magnificent Severn set to save lives for another 25 years - rnli.org

WASHINGTON In a move with sweeping consequences for the US Navy's battle force, the service is canceling plans to add 10 years to the expected service lives of their stalwart destroyer fleet, a cost-savings measure that would almost certainly hamper plans to grow the size of the fleet.

In written testimony submitted to the Senate Armed Services Committee, the Navy's Assistant Secretary for Research, Development and Acquisition James Geurts said performing service-life extensions on Burkes designed to bring them up from 35-year hull lives to 45 years was not cost effective.

"Service life extensions can be targeted, physical changes to specific hulls to gain a few more years, or a class-wide extension based on engineering analysis," the testimony reads. "The Navy has evaluated the most effective balance between costs and capability to be removing the service life extension on the DDG 51 class."

Army takes 40-mile shots from extended-range cannon in demo

The Navy's destroyers are the workhorses of the fleet, with sailors spending an average of one in every four days underway, the highest rate in the fleet, according a recent report from Defense News sister publication Navy Times.

The decision to ax the service life extensions for the Arleigh Burke class comes after years of assurances from Navy leaders that the destroyers would be modernized with an eye to growing the fleet over the coming decades. Navy leaders have offered assurances that the fiscal year 2021 budget continues to grow the fleet despite its significant cuts to shipbuilding and existing force structure, but it is unclear how the fleet will continue to grow past the next five years if service life extensions on the earliest Burkes don't go forward right away.

It would also seem to have significant impact on the current push from Acting Secretary of the Navy Thomas Modly to grow the fleet to 355 ships in a decade.

US Navy guided-missile destroyer USS Dewey conducts a Tomahawk missile flight test in the western Pacific, August 17, 2018. US Navy/MCS 2nd Class Devin M. Langer

In its FY2020 30-year shipbuilding plan, the Navy said extending the lives of the Arleigh Burkes was an imperative to growing the fleet to a battle force of 355 ships. Instead, the cancellation of the service life extensions means that between 2026 and 2034, the Navy is slated to lose 27 destroyers from its battle force.

Those losses would compound the impact of cutting 10 ships from the five-year projections in the 2021 budget, including five of the 12 proposed Flight III Arleigh Burke-class destroyers from the 2020 budget and a Virginia-class attack submarine.

The Defense Department has yet to submit its FY2021 30-year shipbuilding plan, which means that it's impossible to tell how the Navy thinks these cuts would affect its total ship count in the years when it would lose Burkes at a rate of more than three per year.

Europe ship-killing missile passes first firing trial

But the Burke retirements would begin in 2026 or 2027, years just after the service had completed shedding 13 cruisers from its fleet, leaving just nine of the Navy's largest combatants in the fleet.

In a statement, Capt. Danny Hernandez, spokesman for Geurts, said there are a lot of variables in getting the fleet to its goal of 355 ships, but that the Navy's top priority is keeping the recapitalization of its retiring Ohio-class ballistic missile submarines on track.

"Like Navy leaders have stated during testimony, the tradeoffs were complex to get the right balance," Hernandez said.

Sailors aboard guided-missile destroyer USS Nitze man the rails during sea and anchor detail in Duqm, Oman, November 29, 2016. US Navy/MCS 3rd Class Casey J. Hopkins

According to a Naval Sea Systems Command document obtained by Defense News in 2018, the earliest Arleigh Burke destroyers 27 so-called Flight I destroyers have an expected hull life of 35 years. The lead ship, the Arleigh Burke, was commissioned in 1991, meaning its hull life is up in 2026.

DDG-51 through DDG-78 the Flight Is were commissioned between 1991 and 1999. Later models Flight II and Flight IIA have 40-year hull lives.

In 2018, then-Deputy Chief of Naval Operations for Warfare Systems Vice Adm. Bill Merz told USNI News that there were distinct advantages to upgrading the entire class, and that instead of just a combat systems modernization aimed at boosting ballistic missile defense systems, the ships would get the full hull and mechanical upgrades that would extend the ships out to 45 year service lives.

Japan commissions its first submarine running on lithium-ion batteries

"This is an HM&E (hull, mechanical and electrical) extension, but every destroyer is already in the modernization pipeline, so every destroyer will be modernized," Merz said. "The modernization they receive that's already programmed may carry them through.

"Obviously, the threat's going to get a vote on that, but one of the beauties is, instead of doing an individual ship-by-ship extension and extending the entire class, now we have the visibility to actually plan for that. We can pace it, plan it, fund it efficiently instead of one-and-done, one-and-done, one-and-done. We can be a lot more deliberate about how we handle this class."

In testimony that year, Merz said ballistic missile defense was the biggest requirement driving the retention of the DDGs to 45 years.

Sailors on Arleigh-Burke class guided-missile destroyer USS Jason Dunham pose for a command photo, December 2, 2018. US Navy/Mass Comm Specialist 2nd Class Jonathan Clay

Compounded with cuts to the Flight III destroyers, it seems likely that the Navy by 2034 will have a significantly reduced ballistic missile defense capability with at least 32 fewer BMD-capable destroyers in the fleet, if this budget is enacted.

When asked during its FY2021 budget rollout if the cutting of five Flight III DDGs corresponded to a reduction in demand for ballistic missile defense-capable ships, Navy budget director Rear Adm. Randy Crites told reporters it was a decision based on "strictly affordability."

The Navy has in recent years declared the Arleigh Burke hull design maxed out, with the Flight III being packed to the gunwales with power and cooling to support the inclusion of Raytheon's SPY-6 air and missile defense radar. Future combatants will have to accommodate more power generations and storage to support systems such as laser weapons and rail guns.

The US Navy's top officer declares support for basing 6 destroyers in Spain

The excess electrical power capacity in the Ford-class aircraft carrier, for example, is one of the main reasons the Navy considers the new class valuable even as aircraft carriers become more vulnerable to high-speed anti-ship missiles.

Bryan Clark, a retired submarine officer and senior fellow at the Hudson Institute who recently authored a study with the Center for Strategic and Budgetary Assessments that called for canceling the DDG service life extensions, said the cuts were a necessary step.

"It's crazy to throw good money after bad for a bunch of ships you say you don't need," Clark said. "I think the Navy is coming to grips with the fiscal realities; the unsustainable nature of their current plan; and the recognition it is going to have a need for fewer large surface combatants in the future and needs to husband its resources to build a larger fleet of smaller surface combatants. Those are going to be the bulk of the distributed force they intend to have."

Read this article:
The Navy is scrapping plans to extend the lives of its workhorse destroyers - Business Insider - Business Insider

Israels Elbit Systems will supply satellite communications on-the-move for Canadian Armed Forces in a deal with Rheinmetall Canada.

The company did not release the value of the contract, which is part of the Land Command Support System Life Extension program (LCSS LE) program.

The deal, announced March 3, will involve triple-band ELSAT 2100 SATCOM on-the-move (SOTM) systems that aid in real-time broadband communications for moving vehicles. It will use military and commercial satellites, including the U.S. Air Forces Wideband Global SATCOM constellation.

Haim Delmar, executive vice-president and general manager of Elbit Systems C4I and cyber Division, said the company is focusing on delivering technology to whats known as the Five Eye countries, which include the United States, Canada, New Zealand, UK and Australia. Elbits high technology have seen recent deals in most of those countries.

The program is part of Canadas integration of command-and-control system and subsystems and is intended to expand vehicle network equipment as well as enable connectivity with deployed vehicles and headquarters. One of those aspects is new satellite communications installed on what Canada says is a range of Army tactical vehicles to improve both command and control and the sharing of intelligence, surveillance and reconnaissance information while mobile.

The primary contractor has been Rheinmetall Canada since 2014. The initial contract foresaw 110 mobile and five transportable terminals.

The 2100-ELSAT SOTM systems, according to Elbit, will enable the Canadian Armed Forces to maintain long-range voice and data connectivity between mobile command vehicles, liaison elements, high-priority sensor vehicles, as well as tactical headquarters or command posts. It will provide them with high-capacity network services and battle command on-the-move capabilities. The system is ruggedized and has high download and uplink rates for wheeled and tracked modern vehicles.

Elbit was previously selected by Rheinmetall Canada to supply off-board electronic counter-measures for unmanned surface vehicles in Canada in 2019, as well as taking part in the 2014 Rheinmetall Canada deal for ELSAT 2100 Satellite-on-the-move systems. Elbit called the 2014 deal a milestone at the time.

Follow this link:
Elbit to help supply comms on-the-move for Canadian army - C4ISRNet

Image source: The Motley Fool.

Harpoon Therapeutics Inc(NASDAQ:HARP)Q42019 Earnings CallMar 12, 2020, 4:30 p.m. ET

Operator

Good day ladies and gentlemen, and welcome to Fourth Quarter and Full Year 2019 Financial Results Webcast and Conference Call. [Operator Instructions].

I would now like to turn the call over to Mr. Robert Uhl from Westwicke. Sir, you may begin.

Robert Uhl -- Senior Director of Investor Relations at Westwicke

Thank you, operator, and good afternoon everyone, thank you for joining us. On the call today from Harpoon Therapeutics are Gerry McMahon, President and Chief Executive Officer; and Georgia Erbez, Chief Financial Officer. Following management's prepared remarks we will be conducting a Q&A session.

I will now turn the call over to Georgia Erbez, CFO of Harpoon Therapeutics.

Georgia L. Erbez -- Chief Financial Officer

Thank you, Robert and good afternoon. Welcome to Harpoon Therapeutics webcast and conference call for a discussion of the company's fourth quarter and full year 2019, financial results and a corporate update. Before I turn the call over to Dr. McMahon, I would like to remind you that today's call will include forward-looking statements. These forward-looking statements are based on Harpoon's expectations and assumptions as of the date of this call. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon's clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements.

Please refer to Harpoon's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2019, which was filed today and which are also available on Harpoon's website for information concerning factors that could cause Harpoon's actual results to differ from those expressed or implied in the forward-looking statements discussed on this call. Except as required by law, Harpoon assumes no obligation to update any forward-looking statements discussed on this call to reflect any change in the expectations, even as new information becomes available.

I will now turn the call over to Dr. Gerry McMahon, President and CEO of Harpoon Therapeutics.

Gerald McMahon -- President and Chief Executive Officer

Thank you, Georgia, and thank you all, for joining us on the call this afternoon. I am pleased with the achievement of significant clinical, scientific and operational milestones during the past year. We are committed to realizing the promise of our proprietary T-cell engager platform, which we refer to as TriTAC. This T-cell activating construct platform is designed to connect and convert a patient's own T-cells to kill tumors, or other disease tissues. Try near to optimize the therapeutic index of T-cell engagers, and our goal is to bring the successes seen in liquid tumors to solid tumors.

We are currently driving multiple products forward for the potential treatment of cancers and the benefit they could provide to patients, with limited treatment options. Some of the key accomplishments for Harpoon in 2019, included the continued advancement of our lead product candidate HPN424, which is currently in the dose escalation portion of a Phase I clinical trial in patients with prostate cancer.

We are also advanced our pipeline of three other TriTAC programs, including our second product candidate HPN536, which entered the clinic in April 2019, for the potential treatment of mesothelin expressing tumors, with an initial focus on ovarian cancer. We submitted an IND for our third product candidate, HPN217 at the end of last year, and we expect an initiate Phase I/II clinical trial for multiple myeloma in the first-half of 2020. Submission of an IND and initiation of a Phase I trial for HPN328, targeting DLL3 for small cell lung cancer and other tumors, is planned for the second-half of 2020.

Harpoon also strengthened its financial position in 2019, significantly, with our successful initial public offering in February, that raised approximately $70.7 million of net cash. As part of our partnering strategy, we evaluate opportunities to enhance our assets and inflection points that can bring the highest value to our shareholders. As an example of this strategy, in November last year, Harpoon and AbbVie announced an exclusive worldwide development and option transaction for HPN217 targeting BCMA, and in addition, an expansion of our existing discovery collaboration for up to six additional targets. These transactions were a major accomplishment for Harpoon in 2019, and we were pleased to have the opportunity to expand our relationship with AbbVie, and to further align our HPN217 asset, with a partner in multiple myeloma.

Under the terms of the development and option agreement, Harpoon granted AbbVie an option to license worldwide exclusive rights to HPN217, which may be exercised after completion of a Phase I/II clinical trial. This agreement represents a potential transaction value, up to $510 million in upfront option fee and milestone payments, royalties on global commercial sales.

In December, we received a $30 million upfront payment, and we expect to receive up to $50 million as a milestone payment, upon dosing the first patient in the HPN217 clinical trial, which we expect to accomplish in the first half of 2020. In addition, the expanded discovery collaboration represents a deal transaction value of up to $1.86 billion, and in December, we received a $20 million upfront payment under this expansion deal. The financial resources from these transactions are being put to work to support our clinical development and research programs, leading to multiple potential value creating milestones for our shareholders.

Now, let me review some key aspects of our TriTAC technology and after that, I will describe our clinical development programs. Harpoon's TriTAC technology platform is a novel and proprietary approach to engage T-cells. T-cell engagers are engineered proteins that physically connect a patient's own T-cells to target cells, that express its specific proteins or surface markers. This results in the activation of T-cells unleashing their natural power to kill the target cell by releasing potent cytokines and other factors.

Our current pipeline of product candidate focuses on oncology applications of our technology. Unlike other immuno-oncology approaches, like checkpoint inhibitor products, TriTACs do not rely on the existence of tumor specific T-cells, or recognition of the tumor cell through a T-cell MHC interaction. TriTACs can reprogram any T-cell to kill in the absence of MHC recognition and provide an alternative to checkpoint drugs such as PD-1 antibodies.

The first T-cell engager, also known as a BiTE or Bispecific T-cell Engager, was approved in 2014 for the treatment of acute lymphocytic leukemia. However, this first generation technology is limited by a short-half life, and must be administered through continuous intravenous infusion. With our TriTAC platform, we set to incorporate the appealing strengths of BiTE's, such as their small size and potent killing activity at low expression levels of tumor antigen, which are ideal for application in solid tumors, while improving on the administration limitations of the short-half life. Our TriTACs are modular by design, consisting of three primary components that perform three different functions; T-cell binding, half-life extension, and tumor cell binding. To address half-life extension, we utilized a domain that binds transiently to human serum albumin. We utilized single domain antibodies for target binding and human serum albumin binding, which makes our molecules smaller and more flexible than would be possible with larger antibody derived fragments.

Furthermore, these domains are inherently very stable, contributing to a platform that potentially has very little off target activity, and therefore expected to have a therapeutic window that is ideal for applications in solid tumors. Our TriTAC products or globular proteins that can be formulated in solution, and administered to patients by intravenous delivery in about an hour, infusion every one or two weeks. A TriTAC protein is approximately 50 kilodaltons, or about one third the size of a typical antibody. We believe the smaller size and shape of TriTACs allows them to diffuse more freely into tumor tissue, compared to antibodies.

Our TriTACs are about 75% identical to each other. Since the tumor target domain is the only component that varies between different clinical candidates. In addition, our TriTAC use standard methods of conventional, antibody based manufacturing techniques, which avoids the cost and complexity of personalized or cell based therapies such as CAR-T.

Now let me review where we are with our four pipeline development programs; our lead TriTAC product candidate HPN424 targets prostate specific membrane antigen or PSMA, for the treatment of metastatic castration resistant prostate cancer. PSMA is present in 85% to 90% of patients with advanced metastatic prostate cancer. Market research shows us that prostate cancer is the third leading cause of cancer death in the United States. There are approximately 164,000 new cases and 29,000 prostate cancer deaths, in the United States each year.

HPN424 is in a Phase I clinical trial, enrolling patients with metastatic castration resistant prostate cancer. The trial was designed with an initial dose escalation phase, followed by a dose expansion phase. We continue to enroll patients in the dose escalation phase of the trial, with the goal of entering an expansion phase of the trial in the second-half of 2020. Preliminary results announced early last year, suggested that HPN424 could activate T-cells in a manner consistent with tumor target engagement. These data also provided the first clinical evidence that the TriTAC platform has sufficient serum exposure to support weekly intravenous administration. We've continued to enroll patients in the trial, and have continue to increase the dose.

We have submitted an abstract with the intent to provide a trial update at the upcoming ASCO annual meeting in late May or early June. You can expect the data to include an interim look at the ongoing dose escalation phase of the trial. This data may include the number of dose cohorts, the number and features of enrolled patients, the doses explored in the escalation phase at the time of the presentation and preliminary measurement of drug safety, evidence for target engagement pharmacokinetics, pharmacodynamics and early evidence of clinical activity. We expect that dose escalation will continue beyond the data provided in the presentation at ASCO, and anticipate entering a dose expansion phase in the second-half of 2020.

Our second TriTAC product candidate HPN536 targets mesothelin and enter the clinic in April of 2019. It is being studied initially in platinum refractory ovarian cancer, and recently we've added our first metastatic pancreatic cancer patients to this trial. Mesothelin expressed on malignant cells of ovarian carcinoma, pancreatic carcinoma, mesothelioma, non-small cell lung cancer and breast cancer among others. While mesothelin has been the focus of some CAR-T efforts, HPN536 is the first mesothelin targeted T-cell engager to enter clinical development. Patients receive weekly infusions of HPN536 and the trial is proceeding in line with our expectations. The experience we have gained from HPN424 in prostate cancer has been beneficial in our conduct of the 536 trial, and we expect to provide interim data from the ongoing dose escalation portion of the trial, in the second-half of 2020.

Our third TriTAC product candidate HPN217, targets B-cell maturation antigen, or BCMA. We submitted an IND for HPN217 in late 2019, and are planning to initiate a Phase I/II clinical trial in the first-half of 2020, in the treatment of relapsed refractory multiple myeloma. As mentioned before, under the agreement with AbbVie, they will have an option to exclusively license this program upon completion of the Phase I/II clinical trial.

HPN328 is our fourth TriTAC product and it targets delta like ligand 3 or DLL3, a protein highly expressed in a majority of small cell lung cancer tumors and other neuroendocrine tumors. We presented preclinical data at the NCI-EORTC, AACR meeting in October 2019, demonstrating potent tumor cell killing pharmacokinetic data, supporting at least once weekly dosing and supportive safety data in nonhuman primates. We plan to submit an IND for HPN328, and begin a Phase I clinical trial in the second-half of 2020.

This past year has been a strong period of pipeline advancement. We are on track to meet our previously stated goal of having four programs in the clinic by the end of 2020. We look forward to providing additional clinical data from all product candidate programs over the next couple of years. We have a unique off-the-shelf platform for T-cell engagers that reprogram a patient's own immune cells to treat a wide variety of human malignancies. Our pipeline is well positioned to generate exciting data and drive shareholder value.

With that, I'll turn the call over to Georgia Erbez, for a discussion of our financial results, for the fourth quarter and full year 2019.

Georgia L. Erbez -- Chief Financial Officer

Thank you, Gerry. I will provide a brief overview of our financial results here on the call and invite you to review our 10-K filed today for a more detailed discussion. Revenue for the fourth quarter ended December 31, 2019 was $2.2 million, compared to $1.1 million for the fourth quarter ended December 31st, 2018. Revenue for the year ended December 31st, 2019 was $5.8 million, compared to $4.8 million for the prior year. Revenue consisted of the portion of the upfront payment received from our agreements with AbbVie, that was related to research and development services performed during the period.

Research and development expense for the fourth quarter of 2019 was $12.7 million, compared to $8.7 million for the fourth quarter ended December 31, 2018. R&D expense for the year ended December 31st, 2019 was $41.6 million compared to $26.4 million for the prior year. The increase is primarily due to clinical development expenses and an increase in personnel related expenses, including conducting preclinical studies, the continuation of clinical trials for HPN424 and HPN536, and manufacturing activities for our four TriTAC product candidates in various stages of development.

General and administrative expenses for the quarter ended December 31st, 2019 were $4.3 million compared to $2.2 million for the fourth quarter of 2018. General and administrative expenses for the year ended December 31st, 2019 were $22.4 million compared to $6.1 million for the prior year. The increase was primarily due to an increase in legal fees, consulting and accounting services, and an increase in headcount and other professional services to support our ongoing operations as a public company. Net loss for the fourth quarter ended December 31st, 2019 was $14.3 million, compared to $9.7 million for the fourth quarter ended December 31st, 2018. Net loss for the year ended December 31st, 2019 was $55.6 million compared to $27.4 million for the prior year.

We ended 2019 with $155.1 million in cash and cash equivalents compared to $89.5 million as of December 31st, 2018. Net cash provided by financing activities for the year ended December 31st, 2019 was $71.4 million, primarily comprised of $70.7 million in net cash proceeds, received from our initial public offering in February 2019. Net cash used in operations for the year ended December 31st, 2019 was $69.3 million. For 2020, we are estimating cash operating expenses and capital expenditures of approximately $60 million to $70 million.

The cash balance at the end of 2019 includes the $50 million upfront payment received from AbbVie in December, associated with the development and option agreement for HPN217, and the expansion of the existing discovery collaboration. Under the terms of the agreement, we expect to receive up to another $50 million payment, which will be triggered upon the first patient dose with HPN217. We anticipate the payment will be recognized in our quarterly income statement over the next 10 to 12 quarters. As a reminder, while we will recognize the cash payments from AbbVie as quarterly revenue, as required by GAAP. The quarterly revenue is not actual cash received in a period and does not offset cash expenses incurred in the period.

With that, I will now turn the call back over to Gerry.

Gerald McMahon -- President and Chief Executive Officer

Thank you, Georgia. I am very pleased with the tremendous progress Harpoon has made during the past year, the momentum with which we have entered into 2020, and the exciting potential for all of our product candidates in the proprietary TriTAC tech platform. Two of our product candidates HPN424 and HPN536 are in the clinic, and two more HPN217 and HPN328 are expected to begin clinical trials this year. Our financial position is strong, and we have the resources in place to advance our pipeline.

Before we jump into Q&A, let me quickly review our anticipated near-term milestones. For HPN424 our Phase I dose escalation portion of the clinical trial is ongoing and we submitted an abstract, with the intent to present interim data at ASCO during the second quarter of 2020. For HPN536, the Phase I/II trial is continuing to enroll patients in the dose escalation portion of the trial. We intend to present preliminary data from this trial by the end of 2020. For HPN217, we expect to dose the first patient in the Phase I trial in the first-half of this year, which will trigger a $50 million payment from AbbVie. For HPN328, we are planning for an IND submission followed by initiation of a Phase I trial in the second-half of 2020.

So with that operator, we are now ready for questions.

Operator

[Operator instructions]. Your first question comes from the line of Mr. Jonathan Chang from SVB Leerink. Your line is open sir.

David Ruch -- SVB Leerink -- Analyst

Hi, guys, this is David Ruch on for Jonathan. Thanks for taking our question and congratulations on the progress. First question from us is with regard to HPN424, how are you thinking about the benchmarks for response rate and progression free survival in this late line setting of prostate cancer?

Gerald McMahon -- President and Chief Executive Officer

Thank you for the questions. This is Gerry McMahon. So, we of course, look toward previous treatments in late stage prostate cancer and realized that, that these patients, of course, have various features that make it difficult to assess clinical activity in a traditional way. However, what we do follow and what we feel is very relevant is the time on study for patients, which we feel reflects disease progression, we feel PSA levels is another marker of disease. And of course, evaluation of RECIST in measurable disease in a subset of cancer patients. These have been the traditional hallmarks of clinical activity assessment in this late stage patient population.

David Ruch -- SVB Leerink -- Analyst

Got it. Thank you. Second from us, any additional clarity on the registrational strategy for 536 in terms of the different subpopulations of ovarian cancer. And have you seen any trends with the study enrollment to-date that have helped from this strategy?

Gerald McMahon -- President and Chief Executive Officer

It's a little early to strategize a regulatory path for the various diseases where this product could be used. Clearly, our focus initially is an ovarian cancer. And our goal really is to establish a dose, where we believe clinical impact can be observed in this particular disease. We hope that that dose also translate into clinical benefit for pancreatic mesothelioma, non-small cell lung cancer and breast cancer, but that would have to be proven in the clinic. And of course, having multiple diseases to go after with this product gives us many different potential paths toward registration. But we're still in the early phases of our clinical trials trying to establish a proof of concept dose. And until we get there, we really can't strategize our regulatory strategy at this time.

David Ruch -- SVB Leerink -- Analyst

Great. And then just one more kind of logistical question. For 328, will this study be primarily in patients with small cell lung cancer? Or do you potentially expect to enroll other tumor types? I know you mentioned neuroendocrine on the call earlier in the prepared remarks.

Gerald McMahon -- President and Chief Executive Officer

Yes, I mean, the protocol evolution for that trial is still active and in discussion. The focus will be in small cell lung cancer for sure, but we are entertaining going into other tumor types, where we believe DLL3 is expressed. But that is our intention is to move forward with a small cell lung cancer oriented trial, but also have some flexibility to treat other patients that might express this target.

David Ruch -- SVB Leerink -- Analyst

Awesome. Thank you so much for the clarity there.

Gerald McMahon -- President and Chief Executive Officer

Thank you.

Operator

Your next question comes from the line of Mike Ulz from Baird. Your line is open sir.

Michael Ulz -- Baird -- Analyst

Hey guys. Thanks for taking the question, and congrats on all the progress as well. I just had a few questions on HPN424 and maybe you can just give us a sense of where you are in a dose escalation currently. And if I remember, I think last year at the initial update, you were through the fourth cohort. So just curious where you are currently? And then if you can overlay that with what you think that the therapeutic range is, and how far into that are you at this point? And then I have a follow-up.

Gerald McMahon -- President and Chief Executive Officer

Yes. So we haven't specifically disclosed to-date where we are. What we did mention last August, is we spent last year, spent some time evaluating the use of steroid dexamethasone to mitigate mild CRS symptoms when patients were first being given this product. And at that time in August, we were treating our seventh cohort. So what I can say today, of course, moving into a potential medical presentation in the middle of this year, is that we've exceeded that cohort. And we continue to move the dose up and have really done a very good job mitigating this first dose effect that one sees with T-cell engagers. So that's all I can say at this point. Obviously, we're going to have a nice data set describing those who's in patient cohorts, when we hopefully give our medical conference presentation, but that's all I can say at this point.

Michael Ulz -- Baird -- Analyst

Got it. And then maybe in terms of the dose expansion, you mentioned maybe starting that later this year, but you also mentioned continuing to dose escalate past ASCO. So maybe just big picture if you can talk about how you're thinking about selecting that dose for the expansion? Thanks.

Gerald McMahon -- President and Chief Executive Officer

Yes. It might be worth just describing the trial concept in general. So, the goal of the dose escalation in any study is to determine the maximum tolerated dose, and that's usually dictated by dose limiting toxicities. So, if one were to achieve a maximum tolerated dose, by increasing the dose, the expansion cohort if one was to observe efficacy would be driven off of a dose that was obviously safe enough to proceed. At this point, we have no way to know whether we will achieve an MTD by ASCO and so therefore, we would anticipate if we do not get to a maximum tolerated dose, which is our expectation, then we would continue to dose escalation past ASCO. Again, we may get to a point in the trial and this is our expectation that we're seeing a sufficient efficacy to warrant an expansion cohort to explore a particular dose and regimen, that is not being dictated by the achievement of a maximum tolerated dose. In that scenario, that expansion cohort then would be triggered and we would continue to dose escalate above that dose, because we were not limited at that point.

But yes, there was enough reason to believe that there was evidence of clinical activity to warrant testing a patient population, at a particular dose and regimen. So, what's nice about this protocol is we have lots of flexibility to do expansion cohorts and escalations to generate, quite a bit of data that could be used to guide our decision into future regulatory studies. So, that's really what's going on in this particular trial at this point. Is that helpful?

Michael Ulz -- Baird -- Analyst

Yes, that's helpful. Thank you.

Gerald McMahon -- President and Chief Executive Officer

Okay. Thanks.

Operator

Your next question comes from the line of Yigal Nochomovitz from Citigroup. Your line is open.

Yigal Nochomovitz -- Citigroup -- Analyst

Hi, Gerald, thank you very much for taking the questions. If I could just go back to one of the earlier ones on the benchmarks for 424, and maybe ask the question, but more specifically. In terms of how you're thinking about proceeding with development of this asset, could you speak a bit about how you see the bar for success there in terms of a go-no-go decision? What would you like to see ideally, on PSA responses and RECIST responses, to feel good about taking the asset forward into dose expansions, and then into subsequent studies? Thank you.

Gerald McMahon -- President and Chief Executive Officer

Yes. I think if you look at the history of development in late stage prostate cancer, it became very clear to us and to others, that disease progression is the most likely endpoint to support a registrational strategy in this particular disease. So, the most informative, I think endpoint for any trial will be how long as a patient been on study. Remember, this is a weekly therapy, patient would continue to receive therapy on a weekly basis until disease progression, because that would align to a potential regulatory path.

That being said, any ancillary data to support direct anti-tumor effect either by PSA declines or by RECIST or both, would be supportive of that particular patient who is on study progression free. So, I think the primary focus will be keeping the patient from having a disease progression which ultimately would lead to lethality, but then to have some supportive ancillary data related to PSA declines and RECIST if you could measure. Remember, in this disease, only about 20% of patients are RECIST evaluable, so not every patient will have an ability to assess that.

But that being said, this is a trial which will measure all of those potential parameters to assess clinical benefit. I should mention, in addition to that, of course, we have a suite of other translational activities that are being measured in these patients to support mechanism of action, including cytokine changes, T-cell activation, and other parameters that would also be used to support, whether or not, let's say, clinical activities associated with a mechanism of action. Since the only drug these patients are being given is our drug, there's no combination here. So, any of the activities we observe in these patients, we can attribute directly to our mechanism of action. So, it's a long answer, but it's a complicated disease.

Yigal Nochomovitz -- Citigroup -- Analyst

All right, understood. But so just in terms of specific numbers, I guess you're saying it's a bit early for you to kind of put forth specifics as far as, what might be a threshold level of response rate and things like that. Would you prefer just to see how the data evolve?

Gerald McMahon -- President and Chief Executive Officer

It typically, most physicians would argue in this disease. A patient who stays on study greater than three months is good a patient who stays on study greater than six months is very good. And if that patient is also associated either with PSA declines or with some shrinkage of measurable tumors, that would support the notion that that patient is deriving clinical benefit. But given that this is an escalation study, and not an efficacy oriented study. It's hard to put a percentage on it, but that is the type of data that we're looking to generate to support further advancement of this product. Is that helpful?

Yigal Nochomovitz -- Citigroup -- Analyst

Yes, very helpful. Thank you. Again, I had a technology question. So, you're doing once weekly dosing now as I understand it across the programs. What does the technology allow? What is the potential rather for the technology potentially to extend to say, once every two weeks. Do you have that ability with the platform, or is that that's another level of development?

Gerald McMahon -- President and Chief Executive Officer

Yes. So now, we think, based on the data that we see emerging from both these programs, that it's very feasible to think of either HPN424 or 536, being dosed either weekly or possibly every two weeks. But because we're still measuring the exposure and of course, measuring the efficacy, it's hard to know which is optimal, but conceptually, the platform could be used either way. We would hate to not allow the patient to derive as much benefit from the product as possible in this first clinical trial.

But later, if we felt that the benefit could be maintained by moving to a once every two week regimen, the platform could support it. But it's still too early to make a call on what the ultimate frequency would be. But it's not unreasonable based on what we're seeing with the platform of either being once every week or once every two weeks. But we can't say that with surety at this particular time.

Yigal Nochomovitz -- Citigroup -- Analyst

All right, understood. Thanks very much, very helpful.

Operator

Your next question comes from the line of Asthika Goonewardene from SunTrust. Your line is open.

Asthika Goonewardene -- SunTrust -- Analyst

Hi, guys. Thank you for taking my questions and I appreciate all the progress updates here. So, maybe going back to what discussing the expectations for 424 at ASCO. Totally appreciate that the therapeutic window here for 424 is really broad. So, it's kind of hard for you to -- maybe hard to put answers but maybe could you give some sort of clarity as to how many of the cohorts that you will be presenting at ASCO are in that, which you feel Gerry, is the real therapy to be relevant dose range, and that's something will be the answer right now?

Gerald McMahon -- President and Chief Executive Officer

Excerpt from:
Harpoon Therapeutics Inc (HARP) Q4 2019 Earnings Call Transcript - Motley Fool

VANCOUVER , March 9, 2020 /CNW/ - GREAT PANTHER MINING LIMITED (NYSE American: GPL; TSX: GPR) ("Great Panther", the "Company") today announced its inaugural Mineral Resource and Mineral Reserve Estimate (the "MRMR") for its 100% owned Tucano Gold Mine ("Tucano") in Brazil and updated Mineral Resource Estimates for the two mines at its Guanajuato Mine Complex ("GMC") in Mexico. The Company also provides an update on its Topia Mine in Mexico regarding potential near term interruption of operations as a result of temporary cessation of tailings deposition activities at the existing tailings storage facility.

The MRMR reflects the first mineral resource and reserve estimate undertaken by the Company for Tucano since the Company's acquisition of the mine in March 2019. The MRMR has an effective date of September 30, 2019 and uses a more rigorous approach to mineral resource and reserve estimation at Tucano compared to the June 30, 2017 estimate of the previous operator. The MRMR reflects operating experience since acquiring the mine in 2019 and a better understanding of the mine's geology, and is therefore expected to improve mine forecasting reliability. Internationally recognized mining consultants Roscoe Postle & Associates ("RPA") acted as independent technical qualified persons for the MRMR.

At Tucano, after adjustments for mining depletion since June 30, 2017 , Mineral Reserves are now estimated to be approximately 646,000 ounces, a decline of approximately 489,000 gold ounces relative to the June 30, 2017 estimate. Mineral Resources (excluding Mineral Reserves) declined by approximately 500,000 gold ounces.

At the GMC, estimated Mineral Resources (Measured and Indicated) for the Guanajuato Mine were approximately 3.7 million silver equivalent ounces, up by approximately 1.5 million silver equivalent ounces from the prior estimate dated August 31, 2017 , due to a successful 2019 exploration program (see below for silver equivalency calculation). The mine was placed on care and maintenance in December 2018 pending the completion of a more focused exploration program. The Company believes that the increase in resources, together with ongoing drilling in 2020, could be the basis for a re-start of operations later this year.

Measured and Indicated Mineral Resources for the San Ignacio Mine were approximately 5.0 million silver equivalent ounces, a decline of approximately 6.4 million silver equivalent ounces from the prior estimate effective August 31, 2017 , due primarily to mining depletion of 3.8 million silver equivalent ounces. The new Mineral Resource Estimates for the Guanajuato and San Ignacio mines feature higher silver equivalent grades as a result of the application of higher Net Smelter Return ("NSR") cut off values.

"The completion of the MRMR is an important milestone following our acquisition of Tucano as it provides us with a more solid foundation for understanding the geology of Tucano," said Jeffrey Mason , Interim President and CEO. "While our inaugural update has resulted in a lower reserve and resource estimate, it provides us with a higher level of confidence for future mine and operational planning and the increase in average grades provides additional operational flexibility."

"Going forward we will be aggressively advancing opportunities for resource growth and mine life extension on multiple fronts," added Mr. Mason. "At Tucano, we are drilling new near-mine and regional targets in our more than 2,000 square kilometre, largely under-explored land package. We are also evaluating the potential for upgrading confidence in resources for conversion to reserves, and looking to improve and enhance the existing Prefeasibility Study supporting the development of an underground mining operation at Tucano. At GMC, in addition to the potential re-start of the Guanajuato Mine, we are advancing expanded exploration programs at both the Guanajuato and San Ignacio mines."

The Company expects to release 2019 financial results and provide its annual production and cost guidance by the end of March 2020. As part of the completion of its 2019 consolidated financial statements, and audit of those financial statements by the Company's independent auditors, the Company will assess the carrying value of Tucano based on the March 2019 purchase price. The assessment of carrying value will consider the MRMR which could lead to a material reduction in the carrying value and a corresponding material charge to the Company's income statement. Technical reports compliant with Canada's National Instrument 43-101 Standards of Disclosure for Mineral Projects ("NI-43-101") will be filed on the Company's SEDAR profile within 45 days of this news release.

Opportunities for Mineral Resource Increases and Mine Life Extension at Tucano

Based on a preliminary analysis of the updated reserve estimate (without consideration of resource conversion or underground mining), the Company estimates that its current open pit Mineral Reserves will continue to be mined to the fourth quarter of 2021. The Company has identified four key priorities at Tucano to increase reserves and extend the mine life:

1. Near Mine Exploration

The Company has further refined its previously announced 2020 near mine exploration drilling program of approximately 28,000 metres. The focus of the program will be on replacing ounces to be mined in 2020 and extending the mine life. This further refinement involves the prioritization of ten prospective target areas close to the existing pits. The Company has initiated drilling and expects to evaluate the results of drilling by July 2020 , noting that material drill results will be disclosed as received and analyzed. The evaluation will be used to determine whether to increase the program and/or reprioritize targets.

2. Potential Conversion of Existing Measured and Indicated Resources

The Company is pursuing the conversion of resources to reserves concurrent with ongoing mine planning and optimization. Of the approximately 150,000 ounces Measured and Indicated Resources incremental to the Mineral Reserves in table 1.1 below (excluding underground), the Company believes a portion located just below the reserve pit designs may prove to be economically viable if gold prices continue to prevail at or above the current level of approximately $1,675 per ounce, which compares favourably with gold prices used in the MRMR. In addition, the current Brazilian real to US dollar exchange rate is significantly more favorable than the rate of 3.80 used in the MRMR.

3. Underground Development

The Company continues to evaluate the potential for development of an underground mine below the Urucum North pit, which comprises the 288,000 ounces of underground Tucano Mineral Reserves (see table 1.3 below). A decision on whether to proceed with a Feasibility Study for an underground mine is anticipated in the fourth quarter of 2020, following an underground targeted drill program.

Current underground Mineral Reserves are based on previous designs, adjusted for current costs and cut-off grades ("COG"). Mining of up to 400,000 tonnes of ore per annum is contemplated, at an average grade of 4.13 g/t Au.

4. Regional Exploration

As disclosed in a news release dated February 6, 2020 , the Company initiated a 27,000-metre regional exploration drilling program for 2020 on various concessions that Great Panther holds in an under-explored land package consisting of more than 2,000 km2.

Beyond currently planned drilling, the Company is further collating, refining and reviewing all existing data from previous ownership to prioritize targets according to their geological potential and proximity to Tucano's mill.

Urucum Central South ("UCS") Pit Update

As noted in the Company's news releases on October 7, 2019 and October 15, 2019 , the west wall of the UCS pit underwent slope displacement on October 6 , 2019. Since then, the pit has been closed to mining and the Company has deployed significant effort and resources toward a remediation plan with the assistance of the independent consulting firm Knight Pisold & Co.

Pending completion of the remediation plan, the UCS pit continues to be included in the Company's MRMR, with a Mineral Reserve Estimate (Proven and Probable) of approximately 88,000 ounces of gold and potential for further conversion of Measured and Indicated Mineral Resources at higher gold prices than the Mineral Resource Estimate's US$1,500 per ounce. Current estimates for UCS include conservative adjustments to pit wall configurations based on preliminary geotechnical findings.

The Company believes that the reserves are recoverable but cautions that recovery is subject to further evaluation based on geotechnical data gathering now underway. The data gathering will include the collection of additional geotechnical information from five geotechnical core holes to be drilled commencing in April 2020 .

Following completion of data collection, an assessment will be made as to whether remediation of the UCS pit to mine the current reserves will be completed.If the remediation plan is determined not to be feasible, then the current UCS pit reserves may not be mined.

If the remediation can be implemented as planned, the Company expects to be in a position to begin remedial work on the west wall of the UCS pit during the third quarter of 2020 and to resume ore mining in the fourth quarter of 2020.

Summary of Tucano Mineral Resources

A summary of the estimated 2019 Mineral Resources is shown in Table 1.1 and a comparison with the 2017 Mineral Resources is shown in Table 1.2. Summaries of the Measured and Indicated Mineral Resources are presented in Appendix 1 below.

Table 1.1 Summary of Mineral Resources as at September 30, 2019 , Tucano

Location

Cut-off

Total Measured & Indicated

Inferred

Au (g/t)

oxide or fresh

Tonnes

('000's)

Grade Au

(g/t)

Ounces

('000's)

Tonnes

('000's)

Grade Au

(g/t)

Ounces

('000's)

OPEN PITS OXIDE AND PRIMARY FRESH

Urucum

0.40 or 0.55

4,364

2.08

291

7

3.94

1

Urucum East

0.40 or 0.55

143

2.09

10

0

0.00

0

Tap AB

0.40 or 0.55

1,607

2.33

120

0

0.00

0

Duckhead

0.40 or 0.55

183

2.87

17

12

2.79

1

Total Open Pits

0.40 or 0.55

6,296

2.16

438

18

3.21

2

STOCKPILES

Open Pit

0.50

1,887

0.71

43

0

0

0

Spent Ore

0.50

37

Link:
Great Panther Announces Its Inaugural Mineral Reserve & Mineral Resource Estimate for the Tucano Mine, Updated Mineral Resource Estimate at...

The key objective of Ashwagandha Extract Market 2020-2025 Trends and Global Insights report is to help the user understand the market in terms of its segmentation, influential trends, leading players, market potential, primary and secondary research, and the challenges that the market is facing

Deep researches and analysis were done during the preparation of the Ashwagandha Extract market report. The readers will find this report very helpful in understanding the market in depth. The data and the information regarding the market are taken from reliable sources such as websites, annual reports of the companies, journals, and others and were checked and validated by the industry experts. The facts and data are represented in the report using diagrams, graphs, pie charts, and other pictorial representations. This enhances the visual representation and also helps in understanding the facts much better.

The Key players covered in the Ashwagandha Extract Market research report are:

By Market Players:JIAHERB, RAJMOTI, Xian Sgonek Biological Technology, Arjuna, Baldwa, Phyto Life Sciences, NATURALIN BIO-RESOURCES, Quad Lifesciences, Parchem, Ideal Natural Extract, NOW Foods, Swanson, Life Extension, Solgar, Organic India, Taos Herb Company, Piping Rock, Jarrow Formulas

By ApplicationHealth Products, DrugCapsule, Liquid, Powder

Get Sample Copy of this report at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-ashwagandha-extract-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report?form=request-report-sample

The points that are discussed within the report are the major market players that are involved in the market such as manufacturers, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.

The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. The historical data from 2012 to 2017 and forecast data from 2018 to 2023.

Click to access full report and Table of Content at https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-ashwagandha-extract-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report

The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail. Data and information by manufacturer, by region, by type, by application and etc, and custom research can be added according to specific requirements.

The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.Assess the production processes, major issues, and solutions to mitigate the development risk.To understand the most affecting driving and restraining forces in the market and its impact in the global market.Learn about the market strategies that are being adopted by leading respective organizations.To understand the future outlook and prospects for the market.Besides the standard structure reports, we also provide custom research according to specific requirements.

Purchase the research study @

https://www.abrreports.com/industry-insights/2020-2025-global-and-regional-ashwagandha-extract-industry-production-sales-and-consumption-status-and-prospects-professional-market-research-report/checkout?option=one

Key pointers of the Table of Contents:

Chapter 1 Industry OverviewChapter 2 Production Market AnalysisChapter 3 Sales Market AnalysisChapter 4 Consumption Market AnalysisChapter 5 Production, Sales and Consumption Market Comparison AnalysisChapter 6 Major Manufacturers Production and Sales Market Comparison AnalysisChapter 7 Major Material AnalysisChapter 8 Major Type AnalysisChapter 9 Industry Chain AnalysisChapter 10 Global and Regional Market ForecastChapter 11 Major Manufacturers AnalysisChapter 12 New Project Investment Feasibility AnalysisChapter 13 ConclusionsChapter 14 Appendix

About Us:

ABR Reports (Advanced Business Research Reports) is the premium market research reselling company which offers market research reports to individuals, organizations and industries to enhance and strengthen the decision making process. With associate thoroughgoing list of market research Publishers we tend to cut across over all the business verticals covering 5000+ micro markets and offer market size and share analysis, industry trend, information on products, regional market and keen business insights to our clients.

Contact Us:

Scott HarrisSales ManagerEmail ID: [emailprotected]Phone No.: +1-561-448-7424

See the rest here:
Ashwagandha Extract Market Research Report Insights on 2025 Industry Outlook, Competitive Breakdown, Opportunities and Trends - News Times

newsletters, editors-pick-list,

Keeping the Upper Hunter's Liddell power station open for an extra three years would have disastrous environmental and human health consequences, a national environment advocacy group has warned. It comes as Energy Minister Angus Taylor refused to rule out the possibility that the federal government could spend $300 million to keep the power station open past 2023 or even purchase it directly. Using the results of a 2018 study by Newcastle-based epidemiologist Dr Ben Ewald, Environmental Justice Australia calculated air pollution from Liddell Power station would cause an additional 41 premature deaths if it remained open for an extra three years. The extension would also cause an additional 33 low-birthweight babies and 51 additional cases of type 2 diabetes from exposure to pollutants such as sulfur dioxide and nitrogen dioxide. "Saving taxpayers $300 million is an obvious reason for shredding this ridiculous plan but preventing more people from dying prematurely from serious illnesses like stroke, cancer and heart disease, is a compelling enough reason on its own," Director of Research and Advocacy at Environmental Justice Australia Nicola Rivers said. "The health bill from air pollution costs Australians more than 4000 lives and $24 billion a year. Energy Minister Angus Taylor should stop trying to find ways to keep this ageing and inefficient power station open and put the health of the community first." Liddell's owner, AGL Energy , gave seven years notice that it planned to close the 48-year-old plant by 2023. But Mr Taylor lobbied to keep it open until 2026 and set up the Liddell Taskforce to investigate extending its operations. Department officials have played down reports that the government was about to purchase the power station outright from AGL or provide the $300 million required to keep it operating beyond its forecast closure date. The work of the Liddell taskforce had not yet completed and that the report to be delivered to energy minister Angus Taylor was still being finalised, a budget estimates hearing heard on Tuesday. Mr Taylor also told ABC's 7.30 Report on Monday that a decision on the government's response to the looming closure of the Liddell power station would be made after the taskforce had delivered its recommendations. "I haven't received the final report yet but what I will say is that it is crucial that as... these power stations get older, we have either life extension or replacement and that is to ensure that we have downward pressure on prices," Mr Taylor said. It is estimated that the state's five power stations collectively emit enough uncontrolled air pollution to cause 279 deaths each year. While you're with us, did you know the Newcastle Herald offers breaking news alerts, daily email newsletters and more? Keep up to date with all the local news - sign up here IN NEWS TODAY

https://nnimgt-a.akamaihd.net/transform/v1/crop/frm/UfX4XDhNMhVpTbjzWZdknP/d285ee02-8f98-4ddb-b984-4fe5844ed700.jpg/r13_182_5105_3059_w1200_h678_fmax.jpg

Keeping the Upper Hunter's Liddell power station open for an extra three years would have disastrous environmental and human health consequences, a national environment advocacy group has warned.

It comes as Energy Minister Angus Taylor refused to rule out the possibility that the federal government could spend $300 million to keep the power station open past 2023 or even purchase it directly.

The extension would also cause an additional 33 low-birthweight babies and 51 additional cases of type 2 diabetes from exposure to pollutants such as sulfur dioxide and nitrogen dioxide.

"Saving taxpayers $300 million is an obvious reason for shredding this ridiculous plan but preventing more people from dying prematurely from serious illnesses like stroke, cancer and heart disease, is a compelling enough reason on its own," Director of Research and Advocacy at Environmental Justice Australia Nicola Rivers said.

"The health bill from air pollution costs Australians more than 4000 lives and $24 billion a year. Energy Minister Angus Taylor should stop trying to find ways to keep this ageing and inefficient power station open and put the health of the community first."

Liddell's owner, AGL Energy , gave seven years notice that it planned to close the 48-year-old plant by 2023. But Mr Taylor lobbied to keep it open until 2026 and set up the Liddell Taskforce to investigate extending its operations.

The work of the Liddell taskforce had not yet completed and that the report to be delivered to energy minister Angus Taylor was still being finalised, a budget estimates hearing heard on Tuesday.

Mr Taylor also told ABC's 7.30 Report on Monday that a decision on the government's response to the looming closure of the Liddell power station would be made after the taskforce had delivered its recommendations.

"I haven't received the final report yet but what I will say is that it is crucial that as... these power stations get older, we have either life extension or replacement and that is to ensure that we have downward pressure on prices," Mr Taylor said.

It is estimated that the state's five power stations collectively emit enough uncontrolled air pollution to cause 279 deaths each year.

While you're with us, did you know the Newcastle Herald offers breaking news alerts, daily email newsletters and more? Keep up to date with all the local news - sign up here

Read more:
Environmental Justice Australia urges government to allow power station to close - Newcastle Herald

]]> The system is being deployed on Canadian LAVs. Image: Elbit Systems.

Elbit Systems has been selected to supply its Satellite-on-the-Move (SOTM) communications system to the Canadian Armed Forces Land Command Support System Life Extension (LCSS LE) programme under a deal with Rheinmetall Canada.

Under the contract Elbit will provide the Canadian Armed Forces with the triple-band ELSAT 2100 SATCOM on-the-move system, which provides personnel with broadband communications using both military and commercial satellites.

Elbit Systems C4I & Cyber Division executive vice-president and general manager Haim Delmar said: We are proud of our ongoing work with the Canadian Armed Forces, providing them with networked combat solutions.

We will continue to focus on developing and delivering superior networked warfare technologies to Canada and additional Five Eyes countries.

According to Elbit, the system will allow the Canadian Armed Forces to maintain voice and data communications at long ranges using the US Department of Defence (DoD)s Wideband Global SATCOM (WGS) network.

A key focus of the LCSS LE programme is to improve the network capabilities of Canadas land forces. On top of satellite communications capability, Canada is also looking to improve smaller local network capabilities.

Elbit has in the past provided the ELSAT 2100 to Canada under an earlier contract signed in 2014. In the past year, the company has provided a number of systems to the Royal Canadian Navy including an off-board electronic countermeasure payload for the Hammerhead unmanned surface vessel, also as part of a contract with Rheinmetall Canada.

Originally posted here:
Elbit to supply on-the-move communications system to Canada - Army Technology

The Southern Exposure 2020 trade show was held in Tampa this past weekend. The day before the trade show several educational sessions were held. The first of these sessions was entitled The Plight of Plastics, and consisted of a panel of five people: Janis McIntosh of Naturipe Farms, Natalie Shuman of Apeel Science, Brad Dennis of CKF Inc., Kathy Lawrence of Proseal and Elizabeth Yerecic of Yerecic Label. The panel was led by Anabella de Freeman of Walmart Stores.

De Freeman opened the session by explaining the initiatives taken by Walmart for reducing the use of plastics. She said: Walmart has made the commitment to have 100% recyclable packaging for all our private label products by 2025. Our call to action consists of three parts: use less plastics, make it recyclable, and label it.

After de Freemans introduction, each of the panelists received some time to explain how their company views the plight of plastics and what they are doing to help improve the situation.

Commitment to reduction of plasticJanis McIntosh of Naturipe Farms started by saying: I like to call the situation not the plight of plastics, but rather the opportunity of plastics. Recently, the CPMA released their Plastics Technical Report which showed that plastics is needed in berry packaging. So we need to take this opportunity to innovate our plastic use. The issue doesnt require us to eliminate all plastic, but it does require us to eliminate all plastic waste and make it recyclable. We at Naturipe commit to reducing plastic and increasing recyclability.

She added: Change is good, but its better together. To have the most impact, everyone needs to work together and competitors need to ally themselves with each other. This was an important message reiterated by each of the panelists. An example of this cooperation is the commitment of North American berry growers to use 100% recycle-ready packaging by 2025.

Shelf-life and product protectionPanels like this help us realize how we can evolve and innovate as an industry. At Apeel Science we work together with nature to reduce waste and ensure an abundant future for our planet, said Natalie Shuman of Apeel Sciences.

Plastic packaging is often used to elongate a products shelf life. Apeel Sciences works to extend products shelf-lives through a natural, plant-derived product which helps fight food waste and plastic use. While food waste is a sustainability and environmental issue, it is also an economic issue. Shuman explained that US food businesses lose millions of dollars on food waste.

She says: Plastic packaging has multiple purposes: grouping, protection, marketing and shelf-life extension. At Apeel, we tackle this last purpose to help reduce the need for plastic packaging. Our technology uses the molecular building blocks of plants to help create the optimal microclimate within foods. This helps extend the products shelf-life and gives the industry more time at each step of the supply chain.

Alternative packaging optionsBrad Dennis represented CKF Inc., a Canadian packaging company that offers alternatives to plastic packaging. We work with packaging made out of molded pulp. One of our product lines, EarthCycle, uses an optimal blend of virgin hardwood and recycled corrugate. Each of our products are made in North America, and all the materials are sourced from North America as well.

Besides being made of recycled, non-plastic materials, the company goes a step further: the packaging is certified home-compostable. Other benefits of this type of packaging is an up to 20% shelf-life extension, a reduction of over 90% in single use plastics, as well as a 5% sales increase for retailers, Dennis concluded.

Panelist Kathy Lawrence represented ProSeal, a company originating in the UK, whose range of top seal machinery includes 20 different machines specializing in sealing processes. She said: One of the ways we can reduce plastic is by replacing a clamshell lid by a top seal. Not only does this reduce the amount of plastic in the packaging, it also helps reduce warehouse space. We also work with shelf-life extension solutions. Specific top seal materials help control respiration rates and this can help fight food waste.

LabelingElizabeth Yerecic of Yerecic Label helped explain to the audience the issues they may run into with their product labels. While labels themselves do not contribute to the high source of single-serve plastics, they do contribute to the lack of recyclability of single-serve plastics. In order for labels to be sustainable, they need to have aspects such as degradable additives and friendly inks, said Yerecic.

Another issue with labels is the adhesive. The adhesive needs to be able to wash away during the caustic bath at the recycling facility. This is something that is largely the responsibility of the brand owners to ensure that the labels they use in their packaging has all the right components, Yerecic explains. If a label doesnt meet all the necessary requirements, then it is possible that the entire package will not be recycled.

In order to make headway on the plight of plastics, people in each step of the supply chain need to take responsibility. The general conclusion of the panel was that plastic is a necessary material in the industry, for product protection and other purposes, but the way in which it is used needs some major improvement. While many changes have already been made, the best way to move forward is by allying with competitors. While they might be your competitors within the industry, the goal of creating a better and more sustainable future is a shared goal that can only be reached through combined efforts.

Original post:
Change is good, but it's better together - FreshPlaza.com

The one-year major life extension program on the Ocean Surveyor will begin on April 6, 2020.

(Courtesy Damen Shipyards Group)

Offshore staff

GORINCHEM, the Netherlands SGU, Swedens national geological survey agency, has hired Damen Oskarshamnsvarvet for a major life extension program on the survey and research vessel S/V Ocean Surveyor.

It will include the replacement of the all the machinery, bridge, and auxiliary systems including HVAC and a complete overhaul of all remaining equipment. A key aspect of the project will be the conversion of the propulsion and electrical systems from diesel to diesel electric.

According to Damen, the overall objective of the year-long program will be to deliver a modern, low-impact vessel with a good working environment for both the crew and the scientists working on board and better overall accessibility.

Work will begin on the vessel on April 6, 2020 and is scheduled for completion by March 31, 2021.

Built in 1984 in Norway, the Ocean Surveyor is a twin hull, multi-purpose, survey and ROV support vessel constructed using Kevlar / FRP composite for operations mainly in coastal waters.

Measuring 38 m (125 ft) long and 12 m (39 ft) across, the vessel has accommodation for 15 personnel across 12 cabins and is equipped with DPS as well as various fixed hydroacoustic measuring systems. There are two laboratories on board; a wet lab for sediment and environmental sample analysis, and a space with a gamma spectrometer and sediment x-ray for the detailed study of samples.

Bjrn Bergman, operations manager at SGU, said: Ocean Surveyor is a key platform for many marine surveys conducted in Sweden, not only for SGU, but also for other operators hiring the vessels unique surveying facilities.

Damen Oskarshamnsvarvet won the public tender for the contract.

03/03/2020

Continued here:
Damen to overhaul Swedish survey vessel - Offshore Oil and Gas Magazine

TAMPA, FLThink of what plastic packaging has done for entire categories. From seedless cucumbers to grapes, and especially berries.

Fresh-cut fruit wouldnt exist without plastic packaging.

Plastic packaging serves many functions grouping, protection, and shelf life extension, said Natalie Shuman, director of trade and retail marketing for Apeel Sciences, Galena, CA. There reality is that we cant eliminate all packaging, but there are areas where we can reduce reliance.

Before joining Apeel, a company working to reduce food waste through shelf life extension technology, Shuman helped to introduce the stand up pouch bag to the grape category under the Sun World brand.

When we launched that bag that is now ubiquitous across the produce department, we were thrilled because of what it did for merchandising and sales, she said. But I didnt think we were thinking, at the time, about what it was doing to contribute to this issue of plastic waste.

Shuman participated in a panel discussion of The Plight of Plastic at the Southeast Produce Councils Southern Exposure conference on Feb. 28.

Over the past few decades, single-use plastic packaging has increased tremendously, said Anabella de Freeman senior manager of sustainability for produce for Walmart Inc., Bentonville, AR. Packaged produce now accounts for more than 50% of produce sales at retail, she said.

And whats more, she said, millennial consumers prefer packaged produce.

Walmart has issued guidelines for the supplier community to meet, including reducing plastic and recycling metrics, but it can be difficult.

Why?

What we think of as recyclable often isnt. The numbered guide on many plastic packages (think, No. 1 through No. 7) denotes the type of plastic, not that facilities exist to recycle it.

Everybody thinks that clamshells are recycled, said Janis McIntosh, director of marketing innovation and sustainability for Naturipe Farms, Salinas, CA. Its called wishcycling. Ive been there. They take it right out and stick it in the landfill.

Most municipal recyclers dont take clamshells because they cant handle paper labels. Paper labels turn to a mush that contaminates the caustic bath used to wash the plastic to prepare it to be sold to plastic manufacturers.

Rigid plastic packaging is an essential component of the berry business, McIntosh said, so the industry is collaborating on efforts to make clamshells recycle-ready with a film label that separates from the plastic.

The panel outlined other types of collaboration the industry can take to minimize the environmental impact, and waste, of plastic packaging.

Brands have to drive demand for the solutions, said Elizabeth Yerecic key account manager for Yerecic Label.

As suppliers we cant do anything to push that without the demand from the brand owners, she says.

Panelists also discussed solutions like top-seal plastic and fiber-based containers, combined with a shelf-life extension like Apeel to reduce reliance on plastic packaging.

The biggest roadblock?

Price. It always comes down to price, McIntosh said.

Film labels cost anywhere from 15% to 40% more than paper labels, and the industry also is looking at challenges due to humidity and temperature that may affect the adhesives shelf life.

When asked what how the market will adapt to the higher cost of these packaging solutions, De Freeman the industry has to work together to mitigate cost.

The easy answer is that nobody wants to pay more for anything else, she said. Thats why we need to come together to really collaborate to find solutions that maybe at first have a cost impact, and investment. We can get a return on that investment by lowering the shrink.

Yerecic Label debuted the following video about the challenge of recycling plastic clamshells at Southern Exposure.

Continued here:
The Plight of Plastics in fresh produce - Produce Blue Book

Global Artificial Intelligence in Life Extension Market Size, Status and Forecast 2020-2027

The Artificial Intelligence in Life Extension Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Artificial Intelligence in Life Extension Industry Report is an in-depth study analyzing the current state of the Artificial Intelligence in Life Extension Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Artificial Intelligence in Life Extension Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Artificial Intelligence in Life Extension market. All findings and data on the global Artificial Intelligence in Life Extension market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Artificial Intelligence in Life Extension market available in different regions and countries.

Get sample copy of Artificial Intelligence in Life Extension Market [emailprotected] https://www.reportsandmarkets.com/sample-request/global-litigation-funding-investment-market-report-2019?utm_source=SatPr&utm_medium=34

Top Key players: Sydney-based IMF Bentham Ltd., Apex Litigation Finance, and Many More.

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Artificial Intelligence in Life Extension Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and development plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Artificial Intelligence in Life Extension Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Artificial Intelligence in Life Extension market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Artificial Intelligence in Life Extension market report answer pertaining to the regional reach of the industry

A short overview of the Artificial Intelligence in Life Extension market scope:

Reasons for Buying this Report

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2020-2027

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure Artificial Intelligence in Life Extension Market @ https://www.reportsandmarkets.com/sample-request/global-litigation-funding-investment-market-report-2019?utm_source=SatPr&utm_medium=34

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

[emailprotected]

Ph: +1-352-353-0818 (US)

Link:
Huge opportunity in Litigation Funding Investment Market 2020-2027 with Sydney-based IMF Bentham Ltd., Apex Litigation Finance - News Times

As climate change concerns grow, worldwide efforts to transition to a low-carbon future have also intensified. And although industry analysts agree that the global energy transformation is happening, they are quick to point out that oil exploration activities should not be written off just yet.

Investments in renewable energy have dwarfed upstream spend in recent years. By the end of 2019, investors poured in more than USD 2.5 trillion in increasing global renewable energy capacity, based on estimates by the United Nations Environment Programme (UNEP).

Meanwhile, investment in exploration stood at just USD 60 billion in the same year, as spending in the sector almost halved between 2014 and 2018, according to the International Energy Agency (IEA).

But Bart Cornelissen, who leads Deloitte Middle Easts Energy, Resources and Industrials consulting efforts, believes there is still room for exploration in the low-carbon transition. Exploration will decline over time. But for the time being, it is still very much needed, he says.

As the paradigm shift towards renewable energy shapes oil producers and investors appetite for exploration, Cornelissen also underscores the importance of distinguishing between the short- and long-term perspectives on the industry.

If we look at the longer term, there is an increasing role for less carbon-intensive energy. However, in the near term, we still need a tremendous amount of oil- and gas-related investments, and this is very much driven by the fact that a normal oil field depletes about 7- to 8 percent per year, he explains.

So even if the volume of oil produced remains stable, there is still a need to do a lot of exploration to fill that annual gap. The question is not around oil eventually being taken over by renewables. It is about timing.

Given that certain sectors, such as transportation, are entirely dependent on oil, the world cannot quit fossil fuels right away, he says.

What we need to understand is that even if every car sold today is an electric car,it would still take around 20 to 30 years before all conventional cars are phased out. In that sense, I would say that the future of energy is an evolution, not a revolution, he adds.

Abhay Bhargava, director of Industrial Practice for the Middle East and South Asia at Frost & Sullivan, says the trend of innovating to zero has been a key factor in influencing a reduction in future investments in oil exploration. However, he believes it is incorrect to attribute the decline entirely on the advent of renewables.

Countries will continue their march towards diversifying their energy mix, and increasingly adopt renewables, impacting oil consumption, Bhargava says. We however expect an even greater impact coming from the thrust towards decarbonisation, wherein the world moves towards reducing its carbon footprint, and embracing a circular economy, across all forms of consumption, ranging from near-term measures like electric vehicles to long-term measures that are focused towards energy and resource efficiency.

As a result, he expects oil consumption, and in turn exploration, to continue witnessing a certain decline over the next decade and beyond.

As the energy transition gathers pace, Bhargava says oil companies will focus on enhancing productivity and efficiency of their existing upstream assets, with deferred investments in capital expenditure, unless absolutely necessary.

We can expect this to continue this year, and in the short term. We can also expect increased investments in the relatively newer areas of carbon capture utilization and storage, energy storage, asset reliability and remnant life extension, and Industry 4.0, [which includes] digitalization, analytics, edge computing, sensors, drones, and blockchains, he notes.

Asked about his projections for the upstream industry, Cornelissen predicts the oil market could post a compound annual growth rate of as much as 1% over the next 10 years.

But he warns that near-term developments, including political conflicts, oil production disruptions, or a possible coronavirus pandemic, could have a massive impact on longer-term consumer behavior and the oil market in general.

Criselda Diala-McBride is a Dubai-based freelance journalist with more than 20 years of experience writing and editing articles on oil and gas, finance, aviation, tourism, retail, technology, and property for a range of print and online publications. She can be reached by email at cdiala@gmail.com.

See the rest here:
How is the Renewables Quest Impacting Exploration Appetites? - Rigzone

london-based photographers david vintner and gem fletcher document individuals who form part of the transhumanism culture throughout europe, russia and the united states in their latest collaborative photo series, I want to believe an exploration of transhumanism. the five-year-long project explores the core idea behind transhumanism the belief that human beings are destined to transcend their mortal flesh through technology.

neil harbisson hears color neil harbisson was born with achromatism, a rare disease that renders him colourblind. rather than overcome achromatism, harbisson created a new sense to go beyond the human visual spectrumin 2004 he had an antenna implanted into his skull. the antenna allows him to perceive visible and invisible colours as audible vibrations, including infrareds and ultraviolets.

the photo series by vintner and fletcher illustrates three gradual stages of transhumanism from testing ground, patient zero to humanity 2.0. at the lowest tier, testing ground looks into individuals who have created wearable technology to expand their human abilities, improving everything from concentration to mental health.patient zero studies those who have taken permanent action to become half human and half robot. in the final chapter, humanity 2.0, the transhumanist subjects focus on life extension and immortality.

the work of the individuals in this book demonstrates how optimizing our brains and bodies could revolutionize and redefine humanity. as human architects, we are only limited by our imagination, explains vintner and fletcher.

kevin warrick widely considered as one of the first cyborgs.kevin warrick is a pioneering professor in cybernetics and considered by many as the worlds first cyborg. kevin instigated a series of experiments involving the neuro-surgical implantation of a device into the nerves of his left arm in order to link his nervous system directly to a computer. this enabled him to have a symbiotic connection with a robotic hand. he could control the hand using his own brain signals from anywhere in the world, as well as sense what the robot hand was feeling.

humans are now gods. we are now able to create and design humans, but do humans have the foresight to do it in the right way? questions the photographers.

cyborg arm

for many transhumanists, life extension and immortality is the goal. transhumanism started as early as 1923 and has developed over recent years through the rise of sci-fi themed books, movies and the democratization of technology. as studies on experimental genetic engineering, tissue regeneration and stem cell treatments are also becoming more apparent in todays world, transhumanists hope to extend the life of the human body anywhere from twenty to 500 years longer than the average lifespan.

vintner and fletcher are working together on releasing the photo series as a book, which can be funded on crowd-funding platform kickstarter, here.

moon ribas sensing earthquakesmoon ribas is connected to online seismographs allowing her to perceive the seismic activity of the planet through vibrations in her body. the vibration she feels depends on the intensity of the earthquake. if she is standing in newcastle, she can sense earthquakes happening everywhere from japan to greece. she describes the sensation as having two heartbeats, her biological heartbeat and the earthbeat, which has its own rhythm inside her body.

dr natasha vita-more a leading expert on human enhancement and emerging technologies

dr. aubrey de grey biomedical gerontologist and the chief science 0fficer of SENS research foundation

liz parrish founder of bioviva

dr max more president and CEO of the alcor life extension foundation

patient zero - james young after an accident that left him a double amputee, james young turned to bionics to redesign his body. obsessed with the metal gear solid, he worked with gaming giant konami and prosthetic sculptor sophie de oliveira barata to develop an advanced bionic arm inspired by the computer game.

carbon fibre bionic limb

patient zero - rob spence known as the eyeborg, rob spence lost an eye as a child while playing with his grandfather's shotgun. inspired by a love of the bionic man and his interest in documentary filmmaking, spence created an eye with a wireless video camera inside. the camera is not connected to his optic nerve but sends footage to a remote receiver. over the years, he has created several different aesthetics for the eye, from a realistic 'hidden camera' version to a terminator inspired glowing red version.

patient zero - neil harbisson neil harbisson was born with achromatism, a rare disease that renders him colourblind. rather than overcome achromatism, harbisson created a new sense to go beyond the human visual spectrumin 2004 he had an antenna implanted into his skull. the antenna allows him to perceive visible and invisible colours as audible vibrations, including infrareds and ultraviolets.

image out of rob spence's eyes

new ways of seeing - EYEsect the experimental device aims to recreate the experience of seeing the world like a chameleon, with two single steerable eyes. in changing the way we perceive the world around us, eyesect alters our version of reality enabling new ways to sense and experience our environment.

new ways of seeing - north sense created by liviu babitz and scott cohen, north sense is a small matchbox-sized artificial sense organ that delivers a short vibration every time the user faces north, similar to the biological abilities of migratory birds, extending the human perception of orientation.

new ways of seeing - aisen caro chacin / echolocation the echolocation headphones are a pair of goggles that aid human echolocation. it is designed to substitute the users vision augmenting our spatial awareness with sound, similar to the abilities of bats and whales. the device has both the potential to aid the visually impaired and provide sighted individuals with a new sense.

project info:

title:I want to believe an exploration of transhumanism

artistic director: gem fletcher

photographer: david vintiner

kick starter page: I want to believe

See the original post:
cyborgs, robots, and biohackers: the first-ever survey of transhumanism - Designboom

Are These Penny Stocks On Your Watch List Right Now As Coronavirus Fuels Headlines?

Over the weekend, global headlines continued to see countless mentions of coronavirus cases. While many compare it to the average flu, its global spread hasnt been ignored. While the death toll among young, healthy individuals hasnt become a major concern, the fact that mortality is an issue, has been a focal point. Meanwhile, the broader markets are coming off the worst week since the financial crisis.

However, if you are an active reader of PennyStocks.com, it was actually a huge week for coronavirus penny stocks. Last week saw many of these coronavirus stocks reach highs that were well out of penny stock range. Some even blew clear past $40 per share at times.

While the S&P and Dow posed a comeback at the end of the day, we cant ignore continued concerns over the weekend. The first U.S. death has been recorded while new states are reporting their first cases. Meanwhile, weve got a big week of economic data ahead.

Coming up first, weve got China PMI data to consider. It showed the fastest contraction in factory activity ever in February. This was even worse than during the financial crisis. Meanwhile, the likelihood of a Fed rate cut just got that much greater. Slower non-farm payroll figures from Friday didnt help either.

Read More

Consensus forecasts showed payrolls gaining 175,000, which slowed from 225,000 in January. While the U.S. economy appears increasingly vulnerable to the outbreak, the Fed has said it will act as appropriate in response to evolving risks. On another note, The Bank of Canada will also hold a policy meeting this week.

Some analysts think that the Bank could pre-emptively cut rates. This may be a further indication of whats to come for other central banks. The BoC has been known to move early in certain instances, so further market risk could be in play and in favor of certain penny stocks like gold if this is the case.

Then weve got Super Tuesday to think about. A total of 14 states will cast ballots in favor of their optimal Democratic candidate. Bernie Sanders has been said to hold the lead heading into the week. But Super Tuesday will further shed light on what American Democrats want in a candidate, this week. Given everything at work, there are certain sectors that those investing in penny stocks could be focusing on this week.

First, though gold stocks have dipped amid coronavirus concerns, it doesnt mean they will be counted out by any means. Certainly, broader sector stocks felt the brunt of the latest outbreak. However, given the financial uncertainty and economic shifts, gold stocks have historically presented safe-haven options in the market. There are several gold penny stocks that either held a trend or saw a late-Friday bounce last week.

First, IMC International Mining Inc. (IMIMF Free Report)(IMCX) was one of the only gold penny stocks that didnt pull back aggressively last week. In fact, for most of February, shares traded within a range of high $0.30s to low $0.40s. While its U.S. listing is only about a month old, its Canadian listing shows that momentum has built since the beginning of the year. Around January 8th, the stock traded around $0.25 CAD and managed to reach highs of $0.50 CAD.

In February, the company reported several big developments that could be in focus this month. Aside from appointing a new CFO, IMC International also entered into the early phases of a potential acquisition. IMC signed a letter of intent to acquire Thane Minerals, owners of the Cathedral property in northern British Columbia. The Cathedral Project is in an area called the Quesnel Terrane which is rich in mineralization perfect for gold discovery.

The fact that Cathedral is still in a relatively unexplored portion of the northern Quesnel Terrane could signal an opportunity for the company. Considering the proposed acquisition is in its early phases, the market may be watching closely to see if IMC will formally close. It would present immediate access to the Quesnel Terrane via the Catherdral property. The area hosts past and planned production of 50 billion pounds of copper and 28 million ounces of gold.

Next, Yamana Gold stock (AUY Free Report) could be one of the potentially oversold gold penny stocks to watch next week. Shares plummeted last week as coronavirus fears put a stranglehold on the market. After hitting fresh highs of $4.94 on the 24th, Yamana gold stock pulled back to lows it hadnt seen since mid-January.

Aside from last weeks market fueled sell-off, Yamana has actually performed well. That goes from a price and a fundamental perspective. The companys created a pipeline of highly viable exploration projects and created significant positions across the globe with producing assets. But the next move has Yamana focusing on the longer-term.

Yamana has always taken a long-term strategic perspective. We believe that investing in a generative exploration program today will secure our future tomorrow. We have strong prospects in mine-friendly jurisdictions that we know well, and we are confident that they will become a cornerstone of Yamanas next generation of mines.

Yamana has also further optimized its portfolio by shedding assets. For example, last month the company sold off its portfolio of royalty interests and contingent payments from the Deep Carbonates project for $65 million. This is broken up into a $20 million cash component and $45 million share position of which Yamana can further benefit from the potential success of the project.

Similar to Yamana and unlike IMC International, Hecla Mining (HL Free Report) saw its stock drop last week. For Hecla, it was a dip to new 2020 lows. However, in a similar fashion to other gold stocks, HL stock rebounded by the end of the day on Friday. Overall, the sentiment surrounding the company hasnt been bearish.

Earlier last month, the company announced fourth-quarter and full-year 2019 results. Sales for Q4 came in at $225 million with full-year sales hitting $673.3 million marking the highest in company history. Silver production from Hecla came in at 12.6 million ounces along with record gold production of 272,873 ounces. Hecla also reported record reserves for silver, lead, and zinc. Aside from this, the company was able to decrease its net debt by $136 million.

Read More

In 2020, at current prices, we expect continued strong cash flow generation with the ongoing solid performance at Greens Creek, the ramp-up of Lucky Friday, expected improvements at Casa Berardi and the potential mine life extension at San Sebastian from the Hugh Zone, said Phillips S. Baker, Jr., President and CEO of Hecla. During after-hours trading on February 28, Hecla gold stock traded higher at $2.79, which may be something to note if its one of the names on your penny stocks watch list for this week.

After last week, theres no question that biotech penny stocks have taken a spotlight. While some stock saw their biggest drops in recent weeks, many biotech penny stocks reached record highs. In fact, many of these coronavirus penny stocks have been covered consistently for some time now. We put an article out getting everyone up to speed last week Coronavirus Madness: Stocks That Scored Big For Investors. Could these penny stocks to watch join the list this week?

First, Biocept Inc. (BIOC Free Report) was one of the biotech penny stocks discussed in January. At the time the company announced that its Target Selector assays were available to doctors. The focus is for doctors to use the product to evaluate cerebrospinal fluid of patients in checking for tumors. Earlier last month the company reported that it entered into an agreement with a California-based physician association to provide testing services to physicians and patients in that network.

Considering that testing could become a big focus during this outbreak, Biocept appears to have gained attention. On Friday, BIOC stock saw one of its biggest days yet. Shares traded from an open of $0.285 as we focused on the company. By the closing bell, the penny stock was at $0.78. While there hasnt been much coronavirus-specific news, as weve seen speculation played a big role with the latest boom in coronavirus penny stocks.

If Biocept is one of the names on your list of penny stocks, keep this information in mind. Hype may need to be factored into this equation. If BIOC is falling into the coronavirus stock category, take particular consideration in the fact that its pipeline is focused on testing for cancerous tumors. Also, keep in mind that BIOC made a dramatic move on Friday and profit-taking could also be something to keep mindful of in the week ahead.

Another one of the coronavirus penny stocks to watch might be Heat Biologics (HTBX Free Report). While most coronavirus stocks have been taking off for days, HTBX stock seems to have just caught attention on February 28. This came after a downtrend for most of the year. Theres no recent news and no new filings. But several popular message board sites are paring HTBX stock with coronavirus-related news.

Similar to Biocept, Heat Biologics focuses on cancer and T-cell stimulation. Nothing on its site nor in its previous updates were related to coronavirus or the common flu. Meanwhile, back in December, the company reported that it had dosed its first patient in a Phase 1 trial of its t-cell treatment, HS-130. Something else to note is that on the corporate site, it shows the company held a 2020 Special Meeting of Stockholders on February 27.

So, while the market digests the latest coronavirus data, HTBX could find itself in the conversation apparently. In a company 8-K filing, the results of the special meeting showed shareholders agreed to each of Heats proposals. This included an increase to authorized shares from 100m to 250m, effecting a reverse split of common stock, as well as updates to its stock incentive plan. The company also approved authorization to issue undesignated preferred stock. In regard to the reverse split, the company gave a ration within a range of 1 share of Common Stock for every 2-50 shares of Common Stock.

Finally, Oragenics Inc. (OGEN Free Report) was one of the top penny stocks to watch in February. Last Friday, that momentum continued to push shares to new 11-month highs after the market close. OGEN stock reached $0.90 after closing the regular session just under $0.75.

The biotech penny stock started moving as it approached an industry presentation date in early February. We also highlighted all of the FORM 4s filed that showed insider movement in the stock. But there could be a few things at work right now to take notice of, mainly the companys focus on infectious diseases. Oragenics reported the completion of enrollment of its Phase 2 clinical trial for AG013 in Oral Mucositis. More specifically, the company previously reported that it plans to deliver the results of its study early this year.

While coronavirus penny stocks are in focus, timing is of importance. Thats also considering the timeline given in recent CDC press conferences too. Given Fridays momentum will OGEN continue to be one of the coronavirus stocks to watch this week? On its website, the company even states:

Oragenics, in collaboration with Precigen, is in the process of developing lantibiotics, a novel class of antibiotics that are known to be active against several life-threatening infectious agents, toward the goal of commercialization for the treatment of infectious diseases in humans.

Pursuant to an agreement between Midam Ventures LLC and IMC International Mining Corp.(CSE: IMCX), Midam has been paid $200,000 for a period from January 7, 2020, to February 14, 2020. Midam has been paid an additional $200,000 and extended its period of coverage to March 14, 2020. We may buy or sell additional shares of IMC International Mining Corp.(CSE: IMCX) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about IMC International Mining Corp. (CSE: IMCX).Full disclaimer here.

Go here to read the rest:
Penny Stocks To Watch This Week; Coronavirus Still A Concern - Penny Stocks

LOS ANGELES, California Fit Foodie Chef and Grow Green Industries, Inc. (GGI) CEO Mareya Ibrahim is set to emcee the 27th annual International Restaurant and Foodservice Show of New York March 8-10, 2020 at the Javits Center in New York City. Side-by-side with both the Healthy Food Expo New York and Coffee Fest, this years event will feature one badge that grants attendees access to all three trade shows.

This is the fourth Healthy Expo event featuring Chef Mareya as the Center Stage Emcee, including the 2018 Los Angeles and Orlando shows. The GGI founder and CEO and author of Eat Like you Give a Fork: The Real Dish on Eating to Thrive will preparing signature dishes.

Mareya is simply magnetic with endless energy and pizazz. She is incredibly knowledgeable of the industry and possesses the talent to amp up attendees and build hunger for our demonstrations, shares Patricia Copela from Clarion UX. We are delighted to have her as a Center Stage emcee and look forward to another wonderful and exciting event!

Its truly an honor to be hosting for the fourth time and sharing the stage with such an incredible lineup of talent, explains Mareya, Attendees are in for such a treat! Theyll gain incredible knowledge from leaders in the industry, try tasty bites and watch how-tos from some of the worlds best chefs.

The Expos main stage is the place to be, so I suggest you grab your seat early and stick around, because you wont want to miss a minute.

Attendees are invited to meet Chef Mareya and her team at center stage. Visit http://www.InternationalRestaurantNY.com for more information and to register for the three-day event. To schedule an interview with Chef Mareya, please contact Leigh-Anne Anderson on leighanne@anderson-pr.com or visit http://www.mareyaibrahim.com, and to learn more about GGI, Inc.s lab-proven line of food safety and shelf life extension products, please visit http://www.growgreenindustries.com.

About Grow Green Industries, INC./ eatCleaner:

Winner of the Worlds Best Technologies Gold Prize, Grow Green Industries, Inc. dba eatCleaner is a Southern California based, Certified Woman-Owned Business leading the way in eco solutions for produce food safety and shelf life extension to inhibit food waste. Co-founded in 2010 by Dr. Shawki Ibrahim, Ph.D. and nationally recognized food safety and clean eating expert, award-winning entrepreneur, chef, author and inventor, Mareya Ibrahim, aka The Fit Foodie, the company is dedicated to providing safe, effective wholesale and consumer products that enhance lives and improve health. Featured on HSN, QVC and reputable retail locations, their award-winning, patented solutions include the best-selling eatCleaner Triple Action Fruit + Veggie Wash and Wipes, eatFresh-FC anti-browning powder, and avoFresh for cut avocados, and are used in schools, homes, retail locations, food-service businesses and produce processing facilities Visit http://www.growgreenindustries.com to learn more.

Read the rest here:
Fit Foodie Chef Mareya Ibrahim to Emcee at the International Restaurant and Foodservice Show Live in New York City - PerishableNews

SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that it will report its financial results for the fourth quarter and year ended December 31, 2019, after the market close on Wednesday, March 11, 2020. Pfenex will host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 PM Pacific Time (4:30 PM Eastern Time).

About Pfenex Inc.

Pfenex is a development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology to develop and improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, Pfenex has created an advanced pipeline of potential therapeutic equivalents, and vaccines. Pfenexs lead product candidate is PF708, a therapeutic equivalent candidate to Forteo (teriparatide injection). PF708 has been approved in the U.S. for the treatment of osteoporosis in certain patients at high risk for fracture, and marketing authorization applications are pending in other jurisdictions. In addition, Pfenex is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology. Pfenex also uses its Pfenex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccines.

Pfenex investors and others should note that Pfenex announces material information to the public about Pfenex through a variety of means, including its website (http://www.pfenex.com/), its investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with its disclosure obligations under Regulation FD. Pfenex encourages its investors and others to monitor and review the information Pfenex makes public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.

Company Contact:investorrelations@pfenex.com

Read the original here:
Pfenex to Announce Fourth Quarter and Year-End 2019 Financial Results on March 11 - Yahoo Finance

Key Point:Retrofitted with more fuel-efficientCFM-56turbojets and benefiting from expanded fuel tanks, theE-6Acould remain in the air up to fifteen hours, or seventy-two with inflight refueling.

In a military that operates Raptor stealth fighters, A-10 tank busters, B-52 bombers and Harrier jump jets, the U.S. Navys placid-looking E-6 Mercury, based on the 707 airliner, seems particularly inoffensive. But dont be deceived by appearances. Though the Mercury doesnt carry any weapons of its own, it may be in a sense the deadliest aircraft operated by the Pentagon, as its job is to command the launch of land-based and sea-based nuclear ballistic missiles.

Of course, the U.S. military has a ground-based strategic Global Operations Center in Nebraska, and land-based transmitters for communicating with the nuclear triad. However, the E-6s sinister purpose is to maintain the communication link between the national command authority (starting with the president and secretary of defense) and U.S. nuclear forces, even if ground-based command centers are destroyed by an enemy first strike. In other words, you can chop off the head of the U.S. nuclear forces, but the body will keep on coming at you, thanks to these doomsday planes.

The E-6s basic mission is known as Take Charge and Move Out (TACAMO). Prior to the development of the E-6, theTACAMOmission was undertaken by land-based transmitter and laterEC-130Gand Q Hercules aircraft, which had Very Low Frequency radios for communication with navy submarines. Interestingly, France also operated its ownTACAMOaircraft until 2001, four modifiedTransallC-160HAstarttransports, which maintainedVLFcommunications with French ballistic-missile submarines.

The first of sixteenE-6sentered service between 1989 and 1992. These were the last built in averylong line of military variants of the venerable Boeing 707 airliner, in particular the707-320BAdvanced, also used in theE-3 Sentry. Bristling with thirty-one communication antennas, theE-6Aswere originally tasked solely with communicating with submerged Navy submarines. Retrofitted with more fuel-efficientCFM-56turbojets and benefiting from expanded fuel tanks, theE-6Acould remain in the air up to fifteen hours, or seventy-two with inflight refueling.

To use its Very Low Frequency radios, an E-6 has to fly in a continuous orbit at a high altitude, with its fuselage- and tail-mounted VLF radios trailing one- and five-mile-long wire antennas at a near-vertical attitude! The VLF signals can be received byOhio-class nuclear ballistic-missile submarineshiding deep underwater, thousands of miles away. However, the VLF transmitters limited bandwidth means they can only send raw data at around thirty-five alphanumeric characters per secondmaking them alotslower than even the old 14k internet modems of the 1990s. Still, its enough to transmit Emergency Action Messages, instructing the ballistic-missile subs to execute one of a diverse menu of preplanned nuclear attacks, ranging from limited to full-scale nuclear strikes. The E-6s systems are also hardened to survive the electromagnetic pulse from nuclear weapons detonating below.

Between 1997 and 2006, the Pentagon upgraded the entire E-6A fleet to the dual-role E-6B, which expanded the Mercurys capabilities by allowing it to serve as an Airborne Nuclear Command Post with its own battle staff area for the job. In this role it serves as a backup for four huge E-4 command post aircraft based on the 747 Jumbo jet. The E-6B has ultra-high-frequency radios in its Airborne Launch Control system that enable it to remotely launch land-based ballistic missiles from their underground silos, a task formerly assigned to U.S. Air Force EC-135 Looking Glass aircraftyet another 707 variant. The E-6s crew was expanded from fourteen to twenty-two for the command post mission, usually including an onboard admiral or general. Additional UHF radios give the E-6B access to the survivable MILSTAR satellite communications network, while the cockpit is upgraded up with new avionics and instruments from the 737NG airliner. The E-6B can be distinguished in photos by its additional wing-mounted pods.

The Mercurys abundant communications gear allows it to perform nonnuclear Command, Control and Communications (C3) operations as well. For this reason, E-6s have at times been deployed to Europe and the Middle East to serve as flying C3 hubs. For example, VQ-4 was deployed in Qatar for three years from 2006 to 2009, where it relayed information such as IED blast reports and medical evacuation requests from U.S. troops in Iraq who were out of contact with their headquarters.

Two Navy Fleet Air Reconnaissance Squadrons currently operate the E-6: VQ-3 Ironmen and VQ-4 Shadows, both under the Navy Strategic Communications Wing 1. These have their home at Tinker Air Force Base in Oklahoma, but also routinely forward deploy out of Travis AFB in California and Patuxent River Naval Air Station in Maryland. At least one E-6 is kept airborne at all times. E-6s on the submarine-communication mission often fly in circles over the ocean at the lowest possible speedfor as long as ten hours at a time. Those performing the nuclear command post mission typically remain on alert near Offutt Air Force Base in Nebraska. The E-6s nuclear mission has also made its operations occasional fodder for conspiracy theorists and foreign propaganda outlets.

The E-6 platform should remain in service until 2040 thanks to a service-life extension program and continual tweaks to its systems and radios. While the Mercury has demonstrated its usefulness as an airborne communication hub for supporting troops in the field, the airborne command post will be considered a success if it never has to execute its primary mission. The heart of nuclear deterrence, after all, is convincing potential adversaries that no first strike will be adequate to prevent a devastating riposte. The E-6s are vital component in making that threat a credible one.

Sbastien Roblin holds a masters degree in conflict resolution from Georgetown University and served as a university instructor for the Peace Corps in China. He has also worked in education, editing and refugee resettlement in France and the United States. He currently writes on security and military history forWar Is Boring.

This first appeared in December 2017. It is being republished due to reader interest.

Image:566th Aircraft Maintenance Squadron personnel assigned to the Oklahoma City Air Logistics Center at Tinker Air Force Base, Okla., are scheduled to begin work on the service life extension program for the Navy's fleet of E-6B Mercury aircraft flown by Strategic Communications Wing One here. (U.S. Air Force photo/Margo Wright)

More:
Study This Plane: It Could Fight a Nuclear War and Kill Billions - The National Interest Online

The report titled, Global Shelf Life Extension Ingredients Market Report, History and Forecast 2018-2026 has been recently published by TMRR. The authors of the report have done extensive study of the global Shelf Life Extension Ingredients market keeping in mind the key aspects such as growth determinants, opportunities, challenges, restraints, and market developments. This analysis will enrich the ability of the companies involved in the global Shelf Life Extension Ingredients market to make precise decisions. The report also emphasizes on the current and future trends in the global Shelf Life Extension Ingredients market, which may bode well for the global Shelf Life Extension Ingredients market in the coming years. Impact of the driving factors on the global Shelf Life Extension Ingredients market growth has been mapped by the report. Besides, factors that are likely to challenge the global Shelf Life Extension Ingredients market growth in the years to come are discussed by the industry experts in the report.

The report thoroughly reviews the manufacturers operating in the global Shelf Life Extension Ingredients market. It offers figures pertaining to revenue, productions, and market share to provide a 360-degree view of it. They have used SWOT analysis to assess internal strengths, weaknesses, external opportunities, and threats. This is expected to help readers understand finer nuances of the market. This research report is presented in such a way that it helps a reader comprehend the market in wider aspects. In order to fulfil that goal, the researchers have divided the report into various chapters. It will provide readers with accurate and exact information, necessary for complete understanding of the market.

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=4578&source=atm

Segmentation

The Shelf Life Extension Ingredients Market is segmented into following,

Based on type, Shelf Life Extension Ingredients Market can be segmented in,

Based in function, Shelf Life Extension Ingredients Market can be segmented in,

Based on application, Shelf Life Extension Ingredients Market can be segmented in,

The researchers have covered the various product type, end user, and application segments in the Global Shelf Life Extension Ingredients Market Report. They have studied the varieties of products available in the market. Assessment of investments and innovation in these products has also been mentioned in complete detail. The application segment also receives spotlight through evaluation of possible usages of products.

The regions covered in the Shelf Life Extension Ingredients Market Report includes Asia Pacific, South Asia, the Middle East and Africa, North America, South America, and Europe. The research report analyses all the factors augmenting each regional market. It provides the historic, current, and forecast figures for them. Changing government policies and political volatility have been discussed at great length in this chapter to offer clarity.

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=4578&source=atm

Highlights of the Shelf Life Extension Ingredients Market Report

The report addresses the following queries pertaining to the Shelf Life Extension Ingredients Market:

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=4578&source=atm

More here:
Shelf Life Extension Ingredients MARKET 2019 REVENUE, INDUSTRY GROWING DEMAND, SIZE, SHARE, BUSINESS OPPORTUNITIES, TOP COMPANIES, REGIONAL OUTLOOK...

Cleveland Bridge UK has continued to grow its activity in the bridge inspection and refurbishment market by securing a landmark project in Nottingham.

Its Bridge Rehabilitation Team will deliver a high-profile seven-month maintenance programme on the citys iconic Trent Bridge, which includes the application of 120m2 of gold leafing to the bridge fascia.

Cleveland Bridge UK will also paint all steel and cast-iron elements of the bridge, covering more than 11,000m2, along with replacing a small number of damaged cast iron parapet components and completing some stonework repairs to the piers and abutments.

In addition to enhancing its cosmetics, the painting of the bridge, which is adjacent to the international cricket ground of the same name and Nottingham Forests City Ground, more importantly provides ongoing resistance to corrosion and degradation of the structure, securing the long-term load-carrying capacity of the bridge.

Part of a 1.1m investment, equally funded between Nottingham City Council and Nottinghamshire County Council, the project draws upon the depth of skills and proven expertise developed by Cleveland Bridge UKs Rehabilitation Team.

With wide experience of project management, inspection and bridge rehabilitation worldwide, the team supports life extension programmes across the UKs bridge network and internationally.

Jim Mawson, Head of Operational Delivery at Cleveland Bridge UK, said: We are very proud to be awarded this prestigious refurbishment project for one of the UKs most iconic city centre bridges.

Working in close collaboration with the city and county councils, our rehabilitation team will apply its extensive experience to extend the lifespan of Trent Bridge, including having the honour of applying the highly-recognisable gold leaf that greets commuters and visitors to the city as they cross the river.

Nottingham City Councils Portfolio Holder for Transport, Cllr Adele Williams, said: With its nearby cricket ground namesake known worldwide, Trent Bridge is an iconic gateway to the city which together with the County Council we are committed to maintaining and keeping looking its best. This re-painting will help to protect and preserve the bridge while freshening it up for many years to come.

Excerpt from:
Bridge Rehabilitation Team secures Trent Bridge maintenance project - Business Up North

Now, where did I put those files again...

A fresh set of usage figures has the notorious Windows 10 October 2018 Update withering on the Redmond vine as uptake of November's jumped-up patchfest climbs.

There was good news today for pretty much everyone as Microsoft's disastrous 1809 update for Windows 10 saw its usage drop from 22 per cent in January to a mere 16.4 per cent in February, according to figures released by ad-slinger AdDuplex.

Over the 90,000 PCs surveyed by AdDuplex, last year's March update continued to top the leaderboard, although the November update strode from 15.2 per cent to 22.6 per cent. The data is culled from the 5,000 Windows Store apps that run the company's SDK and, in the absence of official stats from Microsoft itself, are a handy pointer to where things are at.

Support for 1809 for most editions is due to come to an end on 12 May 2020, and we really can't see any sort of life extension being granted. Support for the previous edition, 1803, ended in November last year for all but Enterprise, Education and IoT Enterprise license owners, but it still commands just under 5 per cent of PCs surveyed.

1809 might, of course, linger a little longer. Known also as the Windows 10 2019 Long Term Servicing Channel (LTSC), enterprises can keep getting mainstream support for the OS until 2024, with the plug finally being pulled on 9 January 2029. As a reminder, 1809 was infamously re-released on 13 November 2018 after a catastrophic debut and "support dates have been adjusted accordingly".

The figures are evidence that, following the hubris of 1809, a more cautious hand is at the Windows 10 tiller these days. Recent releases (particularly the November 2019 Update) have not been rammed with features that the majority of users neither know nor care about. This trend looks set to continue with the next update, due in the coming weeks, which includes a tweaked Linux kernel to please some developers, but otherwise is mostly free of the fripperies that blighted the operating system in previous years.

And that cautious approach has extended to the release cycle the hysteria in 2018 that saw 1803 (the April 2018 Update) garner nearly 90 per cent of the survey are long gone. A slow, more measured rollout of updates on which users have the option of slamming the brakes means that any one version of Windows 10 is unlikely to trouble the 60 per cent mark before the next update arrives.

Things will start getting a tad more interesting again when Windows 10X finally puts in an appearance.

Sponsored: Quit your addiction to storage

Go here to see the original:
The Ghost of Windows 10 Past shrinks back as Microsoft's axeman tiptoes ever closer - The Register

G4S PLC (LON:GFS) hit the skids, sliding 14% to 166.8p, after revealing it is to sell the majority of its conventional cash handling businesses.

The businesses, which raked in around 600mln in revenue in 2019, are being sold to The Brinks Company for an enterprise value (i.e. adjusted for cash and debt) of 727mln.

The deal put paid to hopes of the businesses being hived off and floated as a separate entity.

Topps Tiles PLC(LON:TPT) tumbled as it warned profit before tax for the year to next October will be materially below expectations.

The market had forecast 13.5mln and 14.5mln, which was still below last years 16mln.

The flooring specialist said the home improvement market still has to see post-election improvement, with like-for-like sales dropping 5.5% in the eight weeks to 22 February.

Standard Chartered PLC (LON:STAN) fell 4.5% to 565.2p as it warned shareholders to brace for slower growth than previously expected in 2020.

Income growth for 2020 is likely to be below its medium-term 5-7% target range, the Asia-focused bank said, blaming a combination of the coronavirus with lower interest rates and a softer Hong Kong economy.

A new share buyback of US$0.5bn was also announced, following the purchase of US$1bn last year.

WPP PLC (LON:WPP) slumped 15% to 775p as it reported flat sales and lower profits and an alarming slump in the fourth quarter.

The performance represents a blow for chief executive Mark Reid and his three-year turnaround plan.

While revenues of 13.2bn for 2019 were up 1.4% on the previous year, this was mostly from currency swings, and annual growth was held back as the fourth quarter saw organic net sales turn negative again, falling 1.6% overall, with the US and UK down 4.5% and 3.7%, the Rest of the World down 0.2% and Western Europe up 1.3%.

Cobra Resources PLC (LON:COBR) eased 11% to 1.7p despite bragging about a breakthrough gold fingerprint at its Wudinna project in South Australia.

Cobra said it has identified a unique and distinctive chemical fingerprint for gold mineralisation at the Barns, White Tank and Baggy Green prospects.

The company is now planning the Stage-2 sampling programme, which will focus on infilling sample sites that target extensions to Barns, White Tank and Baggy Green.

Playtech PLC (LON:PTEC) has been a dog stock over the last three years and fell another 12% today to 269p following a profit warning.

The company, which makes online gaming software, said it started 2020 strongly but the last two weeks it has started to see a material impact from changes in normal customer patterns due to COVID-19, which is significantly affecting two of its largest markets.

Accordingly, results for 2020 are likely to be below existing market expectations, Playtech's statement said.

Playtech slumps as two of its largest markets hit by coronavirus https://t.co/uPXHe2XRmp pic.twitter.com/EaPfwfIr62

Phoenix Copper Limited (LON:PXC) saw its shares rise 5.7% to 10.04p after it banged out shares at a significant premium.

The company raised US$2.0mln (roughly 1.54mln) by way of a subscription for new shares (which raised US$1.54mln) and the issue of 12% unsecured loan notes (which raised 459,400).

The subscription shares were sold at 15p each. Directors Marcus Edwards-Jones, Dennis Thomas as Roger Turner bought, in aggregate, 3.24mln shares at the subscription price.

Drax Group PLC (LON:DRX) advanced 4.2% to 270.8p on the back of solid results and a commitment to end commercial coal generation at the Drax Power Station next year.

The deadline for ending the use of coal at the power station is 2025.

The power generator's adjusted underlying earnings (EBITDA) for 2019 rose to 410mln from 250mln the year before, but on a reported basis the company made a pre-tax loss of 2.8mln versus a profit the year before of 13.8mln after a number of exceptional charges relating to restructuring, asset obsolescence charges and derivatives contracts.

BATM Advanced Communications Limited (LON:BVC) says its Bio-Medical division has successfully developed a new diagnostics kit to detect the coronavirus. The kit has undergone testing by several central laboratories and hospitals that have now verified its ability to diagnose COVID-19, added the medical device maker.

Bahamas Petroleum Company PLC (LON:BPC) has this morning announced that it has secured environmental authorisation for the Perseverance-1 well, which is expected to spud in April 2020. The company noted that the authorisation is the conclusion of an extensive and thorough process over many years, involving local and international agencies, independent third-party expert consultants, and extensive engagement across all aspects of Bahamas government.

After Wednesdays close, Bahamas Petroleum also announced a partial conversion of recently issued loan notes. The exploration company last week inked an 8mln arrangement to issue zero-coupon convertible loan notes to a Bahamian based institutional family-office investor. Shortly thereafter it made an initial draw-down of 2.7mln (after fees it received 2.43mln) and it has subsequently received the first conversion notice, for 1.44mln from the first draw-down

Haydale Graphene Industries PLC (LON:HAYD) told investors that it is making significant progress in its collaborations with international partners, though todays interim financial results confirm adverse trends in short-term revenues. Group revenue for the six months ended 31 December amounted to 1.35mln, down 17%, though it also reduced costs and reported that its adjusted operation loss narrowed by 22% to 2.1mln. It ended December with 2.7mln of cash.

ANGLE PLC (LON:AGL) (OTCMKTS:ANPCY), a world-leading liquid biopsy company, announced that Istituto Nazionale Tumori di Milano, Milano, Italy has published the results of work, which assessed the performance of the firms Parsortix system in renal cell carcinoma (RCC) demonstrating its key advantages. The AIM-listed firm said the pilot study suggested that even the presence of a single CTC in a blood sample prior to treatment may predict a reduced progression-free survival.

Greencoat UK Wind PLC's (LON:UKW) said its renewable energy assets are now powering enough electricity to power almost one million homes. In its results statement for 2019, the renewable infrastructure fund said its investments generated 2,386-gigawatt hours (Gwh) of electricity during the year. Net cash generation clocked in at 127.7mln, enabling the company to pay out 93.2mln in dividends (6.94p per share); the company is targeting dividend payments in the current year of 7.1p. The group' net asset value at the end of 2019 stood at 1,842.8mln, which is equivalent to 119.7p (on an ex-dividend basis) per share, down from 121.4p at the end of 2018.

Base Resources Limited (LON:BSE) has hailed a successful ramp-up of its mining operations at the South Dune orebody in Kenya as it delivered results for the first half of its current year. Looking ahead, managing director Tim Carstens said the company will continue to pursue mine life extension opportunities at its Kwale project, where South Dune is located, adding that the company was also in discussions with the Madagascan government regarding fiscal terms for its Toliara mineral sands project.

AFC Energy PLC (LON:AFC) has announced the appointment of its company secretary Graeme Lewis as its finance director with immediate effect. In a statement, the leading provider of hydrogen power generation technologies said Lewis will also retain his role as its company secretary.

Open Orphan PLC (LON:ORPH) has confirmed the appointment to the board of chief financial officer Leo Toole. Bringing more than 20 years experience to the pharma services group, Toole previously held roles with Procter and Gamble, ResMed and Sublimity Therapeutics.

ECSC Group PLC (LON:ECSC), the provider of cybersecurity services, will be announcing its results for the year ended 31 December 2019 on 25 March 2020.

Salt Lake Potash Limited (LON:SO4) (ASX:SO4) has advised shareholders that a new corporate presentation is now available to view on the company's website.

BigDish PLC (LON:DISH), a food technology company that operates a yield management platform for restaurants, announced that an updated research note from Align Research is now available to view online.

BlueRock Diamonds plc, the AIM-listed diamond mining company, which owns and operates the Kareevlei Diamond Mine in the Kimberley region of South Africa said a new corporate presentation will be made available on its website.

See more here:
G4S bins plans to hive off its cash handling business - Proactive Investors UK

The Bronco II said goodbye as the new Ford Explorer arrived in the brands line up of strong and durable SUVs. It quickly got a warm welcome from the consumers in 1991, and it outsold the already-famous SUVs from Jeep and Chevrolet.

The Ford Explorer sold 300,000 units annually for its first-generation model and this increased by 100,000 units annually for its second-generation model, making it the best-selling Ford SUV at that time.

Ford has released six generations of greatness with the Explorer. From day one, the Ford Explorer captured the hearts of the public, and up to this day, it is one of the most well-loved SUVs in the market. It has so many variants, versions and special editions, which people can choose from their liking.

Scroll along to witness how this vehicle transformed intoone worth celebrating. Here are 15 photos capturing the evolution of the Ford Explorer.

The first generation of the Ford Explorer outshines its predecessor, Bronco II, by having a 4 liter Cologne OHC V6 engine, which produces 155 to 160 horsepower, connected to a four-speed automatic or five-speed manual gearbox. It was available in either two or four-door trim, and with four-wheel-drive or rear-wheel-drive system.

The 1993 Ford Explorer Sport was first planned to be trim level only but made its way to have its own model series. It has a wheelbase 10 inches shorter than the regular Ford Explorer, making it easier to maneuver off-road. Unfortunately, its model line was discontinued in 2003.

RELATED:The Real Story Behind The First Ever Ford Mustang

Ford introduced the second generation of the Ford Explorer in 1995. It still runs the same V6 engine, on the other hand, it received essential improvements from its previous version, including rounded body edges for added aerodynamics and more circular headlights and taillights. Its grille had a new look as well.

The 2002 Ford Explorer was the first of the third-generation Ford Explorer. For the first time, this model was completely redesigned, and not based on the Ford Ranger. It featured more interior amenities and advanced ergonomics that could now accommodate two more passengers, making it a seven-passenger midsize SUV.

The Ford Explorer Sport Trac had two generations, and the first one was launched in 1999 as the brands first midsize pickup truck, between the F-150 and the Ranger. The second edition was released in 2006 and was based on third-generation Explorer. Its base engine is a 210-horsepower V6.

Ford created an entirely new automotive genre with the Sport Trac Adrenalin. This vehicle was released in 2007 as the world's first high-performance sport-utility truck. It amalgamates of performance and functionality and can drive with lightning speed. It makes use of a 4.6 liter supercharged Modular V8 engine, which releases 390 horsepower.

RELATED:The Hidden Truth Behind The 2020 Ford Mustang GT500s V8 Engine

The Ford Explorer America concept made its debut at the 2008 North American International Auto Show in Detroit, as a midsize utility vehicle on a unibody platform that gives it a unique silhouette. This vehicle is ideal for everyday chores since it has sliding doors. It is designed as a six-seater.

2011 was the year for the fifth generation Ford Explorer. Based on the Ford Taurus, this SUV has a unibody chassis and a different engine position. The new model was loaded with a fresh engine, a 3.5-liter V6, which produces a stunning 290 horsepower, matched with a six-speed automatic transmission.

The 2013 Ford Explorer Sport was available for a base price of $41,545 and promised a higher level of energy compared to the regular Explorer. It is the only model fitted with a 365-horsepower engine with aluminum block and heads, and bigger brakes. This trim level flaunts a darker exterior approach.

Ford once again introduced another generation of the famous Explorer in 2016. This new vehicle was announced at the 2014 Los Angeles Auto Show, giving a life extension for the long line up of Explorers. It boasts a 2.3-liter turbocharged four-cylinder engine and a brand-new infotainment display that gives the interior an innovative style.

RELATED:15 Facts And Figures About The New 2020 Ford GT

The market was celebrating the arrival of this $21,668 midsize SUV. The 2018 Ford Explorer received a new grille, enhanced fog lights, and revised headlights. It is available with all-wheel-drive or front-wheel-drive, with a 2.3-liter or 2-liter EcoBoost engine, respectively. It can compete head-to-head with SUVs such as the Nissan Pathfinder and Toyota Highlander.

The 2020 Ford Explorer XLT is one of the primary trim levels of the Explorer, along with Limited, ST and Platinum. The XLT trim differs with a standard powertrain that includes a 300-horsepower 2.3-liter four-cylinder EcoBoost engine, linked to a 10-speed automatic transmission that has a unique Selectshift feature.

The 1010 model year of the Ford Explorer is sold at a starting price of $38,981, and it delivers a more excellent turbocharged power. This sixth-gen Explorer has a zero to 60 miles per hour acceleration time of 6.8 seconds. It is also revised on the inside, with an expanded cabin.

The 2020 Ford Police Interceptor Utility does not only look heavy-duty, but it also performs better than the regular Explorer. This vehicle offers more than what you can think of. It boasts a police-spec suspension and tires. As an extreme officer protector, it passed the 75 miles per hour rear-impact crash test.

The rear-wheel-drive 2020 Ford Explorer Limited has an added touch of class, with leather upholstery, and heated seated. Its steering wheel is also heated. Few more upgrades include a wireless device charging, and 12-speaker Bang and Olufsen sound system. This trim also receives power-adjusting mirrors and an automatic liftgate.

NEXT:15 Affordable Track-Friendly Cars You Can Buy In 2020

Next15 Sports Cars With A Top Speed Too Fast For Their Own Good

Chris is a proficient reader and writer. He has written for many publications including TheRichest, TheClever, TheQuiz, and ListVerse. Cars are his passion.

Originally posted here:
15 Photos Capturing The Ford Explorer's Evolution Through The Years - HotCars

Published: 13:56 Thursday 27 February 2020

A Kintore-based firm has announced the appointment of six new recruits as part of a 400,000 investment in the organisation.

FPSO and marine vessel integrity and repair management company, Marine Technical Limits (MTL), has welcomed three software developers, two CAD designers and an equipment technician.

The software developer appointments come as part of a significant investment by MTL to further the development of their PYXIS integrity management system.

The system is used by clients to track and manage the maintenance, inspections and repairs of their assets, offering FPSO operators a more controlled way of maintaining their FPSO, further extending the life of the asset.

Projects Director Calum MacLean said: We are delighted to welcome these six new recruits.

Investing in our employees and bringing onboard young talented people is part of our ethos at MTL.

Their employment comes as part of a 400k investment this year.

We are extending the features of our Pyxis integrity management software to external users and furthering expanding our inspection planning for UAV and ROV surveys.

Further to its recent appointment of staff and expansion in services, Marine Technical Limits directors Matt Lewin and Calum MacLean attended the FPSO Europe Congress 2020 in London last week to discuss their expertise in Asset Life Extension (ALE).

Read more:
Kintore firm invests in new appointments - Inverurie Herald

Last Thursday of every month, Perpetual Life 's doors open from 6 PM -11 PM to South Florida longevity enthusiasts and the health/wellness community. The guest speaker is Dr. Frank Sabatino, Health Director at Balance for Life Retreat, Florida, health center specializing in plant-based vegan nutrition, health rejuvenation, stress management, and therapeutic fasting and detoxification.

WHAT: Dr. Frank Sabatino, Health Director at Balance for Life Retreat, Florida, will be giving a presentation of "The Plant-Based Fountain of Youth, the Science of Healthy Aging." Closing remarks by Bill Faloon, a brief introduction on "The Benefits of Intermittent Fasting," and his monthly updated list of dead billionaires who missed the longevity boat.

WHEN: Thursday, February 27, 2020, at 7 PM. Doors open at 6 PM.

WHERE: 1855 McKinley Street Hollywood, FL 33021

WHY: Dr. Frank Sabatino will be speaking about the Plant-based diet and longevity.

To see this media advisory in a social media press release go to https://medium.com/@knowaging/perpetual-life-present-the-plant-based-diet-and-intermittent-fasting-for-longevity-f08c2b72d8f

RSVP is required via Eventbrite: https://www.eventbrite.com/e/dr-sabatino-plant-based-fountain-of-youth-the-science-of-healthy-aging-tickets-93971817235Email: neal@churchofperpetuallife.orgCall: (954) 6742524

Watch the Perpetual Life live stream on Thursday, February 27, 2020, at 7 PM.https://youtu.be/yxIkSkFO_OA

###

ABOUT DR. FRANK SABATINO:

Dr. Frank Sabatino is a Chiropractic physician who also has a Ph.D. in cell biology & neuroendocrinology from the Emory University School of Medicine. He has done extensive landmark research on calorie restriction, stress, and aging. He has published a number of major scientific papers in some of the most well-respected peer-reviewed journals in the fields of cell biology, endocrinology, and neuroscience.

Frank has also written numerous articles for lay magazines and journals in the areas of clinical nutrition, healthy weight loss, women's hormones, stress management, addiction, and healthy aging. He was featured in a variety of books, news articles, and cable TV programs, including CNN. Dr. Sabatino is a past member of the prestigious Brookdale fellowship in Gerontology and Aging. For more info https://balanceforlifeflorida.com/health-director/

ABOUT BALANCE FOR LIFE HEALTH RETREAT FLORIDA:Balance for Life Retreats is an all-inclusive plant-based wellness program operating in the Wyndham Deerfield Beach Resort located in Deerfield Beach, FL. It offers a comprehensive lifestyle education program that includes 100% whole food plant-based nutrition without any added salt, oil, or sugar. Providing a variety of exercise classes, tai-chi/yoga stress management programs, and healthy detoxification programs that include vegetable juices and medically supervised water-only fasting under the full-time supervision of Health Director, Dr. Frank Sabatino. https://balanceforlifeflorida.com/https://vimeo.com/345005683

ABOUT PERPETUAL LIFE:The Church of Perpetual Life is a science-based church that is open to people of all faiths. We are non-denominational and non-judgmental. We are a central gathering place for humanists, atheists, agnostics, and Transhumanists, as well as people who are Christian, Jewish, Buddhist, and any other faith. What brings us together is our common hope and belief in the option of healthy Radical Life Extension. For more info visit https:// churchofperpetuallife.org; Email: Neal@ChurchOfPerpetualLife.org; Twitter: @LifePerPetual; Facebook.com/ChurchofPerpetualLife (https://www.facebook.com/ChurchOfPerpetualLife); Subscribe on Youtube (https://www.youtube.com/channel/UCe3YnzN28JK2uof7sAv8e3g)

Follow the full story here: https://przen.com/pr/33333094

Continued here:
Plant Based Fountain of Youth - The Science of Healthy Aging presented by Dr. Frank Sabatino, Health Director of Balance for Life Retreat Florida -...